Coherus BioSciences (CHRS) 10-K 29 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Jan. 31, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	CHRS
Entity Registrant Name	Coherus BioSciences, Inc.
Entity Central Index Key	1,512,762
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		39,103,426
Entity Public Float			$ 783.5

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 158,226	$ 150,392
Restricted cash	60	60
Receivables from collaboration and license agreement	1,560	2,417
Notes receivable		1,815
Prepaid assets (includes related parties of $10,901 and $5,990 as of December 31, 2015 and 2014, respectively)	34,743	20,485
Other assets	2,797	2,276
Other assets - related party		1,691
Total current assets	197,386	179,136
Property and equipment, net	10,504	4,472
Intangible assets	2,620	2,620
Goodwill	943	943
Restricted cash, non-current	785
Other assets, non-current	146	50
Total assets	212,384	187,221
Current liabilities:
Accounts payable	25,948	8,778
Accounts payable - related parties	3,548	2,020
Accrued liabilities (includes related parties of $6,122 and $2,997 as of December 31, 2015 and 2014, respectively)	24,133	11,231
Advance payments under license agreement	1,330	1,192
Deferred revenue	49,621	22,800
Contingent consideration	1,245	5,710
Other liabilities	193	52
Total current liabilities	106,018	51,783
Deferred revenue, non-current	45,338	39,899
Contingent liability to collaborator	66,255	27,650
Contingent consideration, non-current		785
Other liabilities, non-current	1,702	347
Total liabilities	$ 219,313	$ 120,464
Commitments and contingencies (Note 8)
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; Shares authorized: 5,000,000; Shares issued and outstanding: no shares at December 31, 2015 and 2014.
Common stock, $0.0001 par value; Shares authorized: 300,000,000; Shares issued and outstanding: 39,005,589 and 33,257,978 at December 31, 2015 and 2014, respectively	$ 4	$ 3
Additional paid-in capital	404,175	254,048
Accumulated other comprehensive loss	(401)	(525)
Accumulated deficit	(409,985)	(186,725)
Total Coherus stockholders' equity (deficit)	(6,207)	66,801
Non-controlling interest	(722)	(44)
Total stockholders' equity (deficit)	(6,929)	66,757
Total liabilities and stockholders’ equity (deficit)	$ 212,384	$ 187,221

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accrued liabilities including related parties	$ 6,122	$ 2,997
Preferred stock, par value	$ 0.0001
Preferred stock, shares authorized	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	39,005,589	39,005,589
Common stock, shares outstanding	33,257,978	33,257,978
Prepaid assets	$ 34,743	$ 20,485
Prepaid Clinical, Material, Manufacturing and Other - Related Parties
Prepaid assets	$ 10,901	$ 5,990

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue:
Collaboration and license revenue		$ 30,041	$ 30,374	$ 2,751
Other revenue			732
Total revenue		30,041	31,106	2,751
Operating expenses:
Research and development (includes related party of $42,768, $21,723 and $9,471 for the years ended December 31, 2015, 2014 and 2013, respectively)		213,062	78,224	31,279
General and administrative (includes related party of $559, $597 and $18 for the years ended December 31, 2015, 2014 and 2013, respectively)		36,046	17,564	7,465
Total operating expenses		249,108	95,788	38,744
Loss from operations		(219,067)	(64,682)	(35,993)
Interest expense (includes related party of $2,687 and $4,026 for the years ended December 31, 2014 and 2013, respectively)		(33)	(3,900)	(5,293)
Other expense, net		(4,838)	(18,595)	(12,349)
Net loss		(223,938)	(87,177)	(53,635)
Net loss attributable to non-controlling interest		678	44
Net loss attributable to Coherus		$ (223,260)	$ (87,133)	$ (53,635)
Net loss per share attributable to Coherus, basic and diluted		$ (6.01)	$ (10.64)	$ (16.10)
Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted		37,122,008	8,186,529	3,332,020
Baxalta License Agreement
Revenue:
Collaboration and license revenue		$ 27,802	$ 28,481	$ 726
Daiichi Sankyo - Related Party
Revenue:
Collaboration and license revenue	[1]	$ 2,239	$ 1,893	$ 2,025
[1]	Represents revenue from Daiichi Sankyo through November 12, 2014 as a related party, a holder of more than 10% of our common stock until the closing of our initial public offering (“IPO”).

Consolidated Statements of Ope5

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Research and development from transactions with related party	$ 42,768	$ 21,723	$ 9,471
General and administrative expenses from transactions with related party	$ 559	597	18
Interest expense from transactions with related party		$ 2,687	$ 4,026

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (223,938)	$ (87,177)	$ (53,635)
Other comprehensive loss:
Foreign currency translation adjustments, net of tax	124	(525)
Comprehensive loss	(223,814)	(87,702)	(53,635)
Comprehensive loss attributable to non-controlling interest	678	44
Comprehensive loss attributable to Coherus	$ (223,136)	$ (87,658)	$ (53,635)

Consolidated Statements of Conv

Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit) - USD ($) $ in Thousands	Total	InteKrin	Common Stock	Common StockInteKrin	Additional Paid-In Capital	Additional Paid-In CapitalInteKrin	Accumulated Other Comprehensive (Loss)	Accumulated Deficit	Total Coherus Stockholder Equity (Deficit)	Total Coherus Stockholder Equity (Deficit)InteKrin	Noncontrolling Interest	IPO	IPOCommon Stock	IPOCommon StockWarrant	IPOAdditional Paid-In Capital	IPOTotal Coherus Stockholder Equity (Deficit)	Follow-On Public Offering	Follow-On Public OfferingCommon Stock	Follow-On Public OfferingAdditional Paid-In Capital	Follow-On Public OfferingTotal Coherus Stockholder Equity (Deficit)	Private Placement	Private PlacementCommon Stock	Private PlacementAdditional Paid-In Capital	Private PlacementTotal Coherus Stockholder Equity (Deficit)	Series A Convertible Preferred Stock	Series A Convertible Preferred StockIPO	Series B Convertible Preferred Stock	Series B Convertible Preferred StockIPO	Series C Convertible Preferred Stock	Series C Convertible Preferred StockIPO
Beginning Balances at Dec. 31, 2012	$ (45,503)		$ 1		$ 453			$ (45,957)	$ (45,503)
Beginning Balances, Shares at Dec. 31, 2012			4,834,467
Beginning Balances at Dec. 31, 2012																									$ 1,191		$ 53,504
Beginning Balances, Shares at Dec. 31, 2012																									972,330		8,181,576
Issuance of common stock upon exercise of stock options	6				6				6
Issuance of common stock upon exercise of stock options, Shares			3,248
Vesting of restricted common stock issued to founders	10				10				10
Stock-based compensation expense	2,045				2,045				2,045
Net loss	(53,635)							(53,635)	(53,635)
Ending Balances at Dec. 31, 2013	(97,077)		$ 1		2,514			(99,592)	(97,077)
Ending Balances, shares at Dec. 31, 2013			4,837,715
Ending Balances at Dec. 31, 2013																									$ 1,191		$ 53,504
Ending Balances, shares at Dec. 31, 2013																									972,330		8,181,576
Beneficial conversion feature related to convertible notes issued in 2013	(3,939)				(3,939)				(3,939)
Issuance of convertible preferred stock for InteKrin acquisition																											$ 3,667
Issuance of convertible preferred stock for InteKrin acquisition, Shares																											960,486
Issuance of convertible preferred stock in exchange for services																											$ 57		$ 100
Issuance of convertible preferred stock in exchange for services, Shares																											8,185		9,997
Issuance of convertible preferred stock net of issuance costs																													$ 54,660
Issuance of convertible preferred stock net of issuance costs, Shares																													5,488,892
Issuance of convertible preferred stock value upon conversion of convertible promissory notes																													$ 10,583
Issuance of convertible preferred stock shares upon conversion of convertible promissory notes, Shares																													1,058,089
Issuance of convertible preferred stock upon exercise of warrants, including the reclassification of the associated convertible preferred stock warrant liability																									$ 1,004		$ 39,277
Issuance of convertible preferred stock upon exercise of warrants, including the reclassification of the associated convertible preferred stock warrant liability, Shares																									62,251		4,574,713
Issuance of common stock												$ 80,209			$ 80,209	$ 80,209
Issuance of common stock, Shares													6,803,702
Conversion of convertible preferred stock and common stock warrants to common stock in connection with initial public offering												$ 164,043	$ 2		$ 164,041	$ 164,043										$ (2,195)		$ (96,505)		$ (65,343)
Conversion of convertible preferred stock and common stock warrants to common stock in connection with initial public offering, Shares													21,316,519	491,580												(1,034,581)		(13,724,960)		(6,556,978)
Issuance of common stock options in exchange for services	48				48				48
Issuance of common stock upon exercise of stock options	55				55				55
Repurchase of unvested founders shares, Value	(2)				(2)				(2)
Repurchase of unvested founders shares			(239,952)
Vesting of restricted common stock issued to founders	5				5				5
Stock-based compensation expense	11,117				11,117				11,117
Cumulative translation adjustment	(525)						$ (525)		(525)
Distributions to non-controlling interest	(44)										$ (44)
Net loss	(87,133)							(87,133)	(87,133)
Ending Balances at Dec. 31, 2014	$ 66,757		$ 3		254,048		(525)	(186,725)	66,801		(44)
Ending Balances, shares at Dec. 31, 2014	33,257,978		33,257,978
Ending Balances, shares at Dec. 31, 2014	0
Issuance of common stock upon payment of InteKrin Earn Out contingency		$ 9,849				$ 9,849				$ 9,849
Issuance of common stock upon payment of InteKrin Earn Out contingency, Shares				358,384
Retired shares resulting from Intekrin escrow distribution in cash				(8)
Issuance of common stock																	$ 112,199	$ 1	$ 112,198	$ 112,199	$ 9,930		$ 9,930	$ 9,930
Issuance of common stock, Shares																		4,137,931				390,167
Issuance of common stock upon exercise of stock options	$ 1,429				1,429				1,429
Issuance of common stock upon exercise of stock options, Shares	861,137		861,137
Vesting of restricted common stock issued to founders	$ 9				9				9
Stock-based compensation expense	16,712				16,712				16,712
Cumulative translation adjustment	124						124		124
Distributions to non-controlling interest	(678)								(678)		(678)
Net loss	(223,260)							(223,260)	(223,260)
Ending Balances at Dec. 31, 2015	$ (6,929)		$ 4		$ 404,175		$ (401)	$ (409,985)	$ (6,207)		$ (722)
Ending Balances, shares at Dec. 31, 2015	33,257,978		39,005,589

Consolidated Statements of Con8

Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit) (Parenthetical) - Series C Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2014$ / shares
Issuance price per share of convertible preferred stock	$ 6
Conversion price per share of convertible preferred stock	6
Exchange price per share of convertible preferred stock for services	$ 6

Condensed Consolidated Statemen

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating activities
Net loss	$ (223,938)	$ (87,177)	$ (53,635)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	1,869	674	404
Remeasurement of contingent consideration	4,599	5,185
Remeasurement of convertible preferred stock warrant and embedded derivative liabilities		15,899	4,557
Fair value of warrants in excess of debt proceeds recognized at issuance			3,669
Fair value of embedded derivative in excess of debt proceeds recognized at issuance			4,096
Preferred stock issued in exchange for services		147	7,579
Non-cash interest (income) expense and amortization of (receivable) debt discount	(38)	3,897	5,293
Gain on extinguishment of 2013 Notes		(2,048)
Impairment of property and equipment	382
Provision for other receivables	1,300
Stock-based compensation expense	16,721	11,062	2,045
Changes in operating assets and liabilities:
Receivables from collaboration and license agreement	857	(2,139)	(120)
Notes receivable	1,853	(1,815)
Notes receivable from related parties		107	16
Prepaid assets	(14,288)	(14,692)	(3,284)
Other assets	(3,329)	(2,046)	60
Other assets - related party	1,691	(1,691)
Other assets, non-current	42	(25)	(21)
Accounts payable	18,404	3,629	924
Accounts payable, related parties	1,528	1,637	(1,310)
Accrued liabilities	12,832	3,949	2,847
Other liabilities	(28)	31	(2)
Deferred revenue	32,294	19,848	34,749
Advance payments under license agreements	138	1,192
Contingent liability to collaborator	38,605	20,150	7,500
Other liabilities, non-current	516	299	56
Net cash (used in) provided by operating activities	(107,990)	(23,927)	15,423
Investing activities
Net cash acquired from acquisition of InteKrin Therapeutics Inc.		2,334
Purchases of property and equipment	(6,164)	(2,849)	(373)
Increase in restricted cash	(785)	(10)
Net cash used in investing activities	(6,949)	(525)	(373)
Financing activities
Proceeds from issuance of convertible preferred stock, net of issuance costs		54,660
Proceeds from issuance of convertible notes			2,900
Proceeds from issuance of convertible notes - related parties			7,050
Proceeds from issuance of convertible preferred stock upon exercise of warrants		131
Proceeds from initial public offering, net of underwriters discounts and commissions		85,419
Proceeds from follow-on offering, net of underwriters discounts and commissions	112,800
Proceeds from private placement	10,000
Proceeds from issuances of common stock upon exercise of stock options	1,429	55	6
Repurchase of restricted common stock		(2)
Net cash provided by financing activities	122,689	135,956	9,956
Effect of exchange rate changes in cash and cash equivalents	84	(666)
Net increase in cash and cash equivalents	7,834	110,838	25,006
Cash and cash equivalents at beginning of period	150,392	39,554	14,548
Cash and cash equivalents at end of period	158,226	150,392	39,554
Supplemental disclosures of noncash investing and financing activities
Contingent consideration accrued in connection with acquisition		1,310
Reclassification of fair value of convertible preferred stock warrants to preferred stock upon exercise		40,150
Vesting of restricted common stock	9	5	10
Purchase of property and equipment in accounts payable and accrued liabilities	1,684	726	$ 169
Leasehold improvements allowance from landlord	1,239
Initial public offering costs in accounts payable		855
Costs related to future offerings in accounts payable and accrued liabilities	124
Accrued expenses settled in common stock warrants		55
Accrued expenses settled in preferred stock		10
Fair value of contingent consideration settled in common stock	9,849
Series B Convertible Preferred Stock
Supplemental disclosures of noncash investing and financing activities
Issuance of Series B Preferred stock for acquisition		3,667
Reclassification of fair value of convertible preferred stock warrants to preferred stock upon exercise		39,300
Series C Convertible Preferred Stock
Supplemental disclosures of noncash investing and financing activities
Conversion of 2013 Notes and accrued interest into Series C convertible preferred stock		10,583
Initial Public Offering
Financing activities
Payments of offering costs	(855)	$ (4,307)
Follow-On Public Offering and Private Placement
Financing activities
Payments of offering costs	(672)
Future Offerings
Financing activities
Payments of offering costs	$ (13)

Organization and Operations

Organization and Operations	12 Months Ended
	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Operations	1. Organization and Operations Description of the Business The Company is a late-stage clinical biologics platform company, focused on the global biosimilar market. The Company’s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. The Company operates in one segment. The Company’s clinical stage pipeline consists of a long-acting form of granulocyte colony-stimulating factor (“G-CSF”), and two anti-inflammatory agents targeting tumor necrosis factor (“TNF”): · The Company’s long-acting G-CSF product candidate, CHS-1701, is being developed as a pegfilgrastim (Neulasta) biosimilar. In October 2015, the Company has completed a pivotal pharmacokinetic (PK) and pharmacodynamics (PD) study for CHS-1701 in the United States (U.S.). Although it did not meet the PK AUC bioequivalence endpoint due to low, anomalous PK profile in the first period Neulasta group, the Company believes this study will support the planned filing of a biologics license application (BLA) in the U.S. as it met all the other co-primary endpoints including the PD endpoints. An immunogenicity study in healthy volunteers pursuant to this BLA met its primary endpoints. In February 2016, the Company initiated a follow-on PK/PD study, which is expected to read-out late in the first half of 2016. The Company expects to file a BLA in the United States directly thereafter. · The Company’s most clinically advanced anti-TNF product candidate, CHS-0214, is being developed as an etanercept (Enbrel) biosimilar that the Company has partnered with Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH, (collectively “Baxalta”) and Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) to develop and commercialize in key markets outside of the U.S. In October 2015, the Company completed part 1 of a Phase 3 clinical study in psoriasis comparing CHS-0214 to Enbrel. The Company is currently conducting a Phase 3 clinical study in rheumatoid arthritis. This study met the primary endpoint at 24 weeks. The Company expects that results from these studies, combined with data from its Phase 1 studies will support the expected filing of a marketing application in Europe and Japan in 2016. The Company has retained the development and commercial rights to this product in the U.S. However, the therapeutic protein in etanercept is subject to certain originator-controlled U.S. patents expiring in 2028 and 2029. Assuming these patents are valid and enforceable, and that the Company would be unable to obtain a license to them, the Company does not expect to commercialize CHS-0214 in the U.S. prior to their expiration. · The Company’s second anti-TNF product candidate, CHS-1420, is being developed as an adalimumab (Humira) biosimilar. This product successfully completed a pivotal Phase 1 PK study in August 2014 by meeting the primary PK bioequivalence endpoint. The Company initiated a Phase 3 study in psoriasis in August 2015 to support the planned filing of a marketing application in the U.S. in 2016 and the E.U. in 2017. The Company initiated a bridging PK study comparing the Phase 3 CHS-1420 material to U.S. manufactured adalimumab (Humira) during the first quarter of 2016 and the Company plans to initiate a bridging PK study comparing the Phase 3 CHS-1420 material to E.U. manufactured adalimumab (Humira) in mid-2016. Need to Raise Additional Capital As of December 31, 2015, the Company had an accumulated deficit of $410.0 million and cash and cash equivalents of $158.2 million. In February 2016, we issued and sold $100.0 million aggregate principal amount of 8.2% senior convertible notes (“Notes”) due March 31, 2022 (see Note 16). .

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Consolidation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The accompanying consolidated financial statements include the accounts of Coherus and its wholly owned subsidiaries as of December 31, 2015: Coherus Intermediate Corp, Coherus Oncology, Inc., InteKrin Therapeutics Inc. (“InteKrin”), and InteKrin’s 82.5% majority owned subsidiary of InteKrin Russia. Unless otherwise specified, references to the Company are references to Coherus and its consolidated subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. Reclassification To maintain comparability among the periods presented, the Company reclassified certain prior period amounts to a separate line item that was not included in the prior period presentation. Within Note 4, Accrued Liabilities, in the Notes to the Consolidated Financial Statements for the year ended December 31, 2014, the Company reclassified amounts that were recorded within accrued other to accrued clinical and manufacturing. The reclassification had no impact on the total current accrued liabilities for the periods presented. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, valuation of deferred tax assets, impairment of goodwill and long-lived assets, the valuation of acquired intangible assets, clinical trial accruals, revenue recognition period, as well as certain accrued liabilities; and in prior years, common stock valuation, the valuations of the convertible preferred stock warrant liability and embedded derivative instruments. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates. Foreign Currency The functional currency of InteKrin Russia, which the Company acquired in February 2014, is the Russian Ruble. Accordingly, the financial statements of this subsidiary are translated into U.S. dollars using appropriate exchange rates. Unrealized gains or losses on translation are recognized in accumulated other comprehensive loss in the consolidated balance sheet. For the years ended December 31, 2015, 2014 and 2013, the foreign exchange gains and losses recorded in other expense, net in the consolidated statements of operations were a net loss of $386,000, a net gain of $671,000 and a net loss of $34,000, respectively. Segment Reporting and Customer Concentration The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing biosimilar products, and, as part of the InteKrin acquisition, small molecules (see Note 6). The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Long-lived assets are primarily maintained in the United States of America. The following table summarizes revenue by geographic region (in thousands): Year Ended December 31, 2015 2014 2013 United States $ 27,802 $ 28,481 $ 726 Rest of world 2,239 2,625 2,025 Total revenue $ 30,041 $ 31,106 $ 2,751 Customer Concentration Customers whose collaboration and license revenue accounted for 10% or more of total revenues were as follows: Year Ended December 31, 2015 2014 2013 Daiichi Sankyo - related party (1) * * 74 % Baxalta 93 % 92 % 26 % * less than 10% (1) Represents revenue from Daiichi Sankyo through November 12, 2014 as a related party, a holder of more than 10% of our common stock until the closing of our IPO. Deferred Offering Costs Deferred offering costs, which primarily consist of direct incremental legal and accounting fee, are capitalized in other assets until the completion of the offering. These deferred offering costs will be reclassified to additional paid-in capital upon the closing of the offering. There was $137,000 in deferred offering costs capitalized as of December 31, 2015 and none capitalized as of December 31, 2014. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Restricted Cash Restricted cash consists of cash held in money market accounts with a bank. The restricted cash that is used as collateral against the Company’s corporate credit cards is classified as current and the restricted cash to cover the standby letter of credit issued for the Company’s landlord to drawdown on if the facility lease is breached, is classified as non-current (see Note 8). Concentration of Credit Risk The Company’s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash in bank accounts which at times exceed federally insured limits. The Company attempts to minimize the risks related to cash and cash equivalents by investing in money markets with a broad and diverse range of financial instruments. The investment portfolio is maintained in accordance with the Company’s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. Fair Value of Financial Instruments Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Maintenance and repairs are charged to expense as incurred, and costs of improvements are capitalized. Depreciation and amortization is recognized using the straight-line method over the following estimated useful lives: Computer equipment and software 3 years Furniture and fixtures 5 years Machinery and equipment 5 years Leasehold improvements Shorter of lease term or useful life Impairment of Long Lived Assets and Acquired Intangible Asset The Company reviews long-lived assets, including property and equipment, and indefinite-lived intangible, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when the estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. For the year ended December 31, 2015, the Company recorded a $382,000 impairment of property and equipment in research and development within the statement of operations. Acquired in-process research and development (“IPR&D”) represents the fair value assigned to research and development assets that have not reached technological feasibility. The Company reviews amounts capitalized as acquired IPR&D for impairment at least annually, and whenever events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of the acquired IPR&D exceeds its fair value, then the intangible asset is written-down to its fair value. As of December 31, 2015, there have been no such impairments. Once the product candidate derived from the indefinite-lived intangible asset has been developed and commercialized, the useful life will be determined, and the carrying value of the finite-lived asset will be amortized prospectively over that estimated useful life. Alternatively, if the product candidate is abandoned, the carrying value of the intangible will be charged to research and development expense. Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The Company tests goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that this asset may be impaired. The goodwill test is based on our single operating segment and reporting unit structure. The Company compares the fair value of its reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of the reporting unit, then the Company would need to determine the implied fair value of the reporting unit’s goodwill. If the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then the Company would record an impairment loss equal to the difference. N o goodwill impairment was identified through December 31, 2015. Convertible Preferred Stock Warrant Liability The Company classified warrants exercisable for shares of the Company’s Series A and Series B convertible preferred stock as derivative liabilities and adjusted their carrying value to fair value at the end of each reporting period as long as such warrants were outstanding. At the end of each reporting period, changes in the fair value of the convertible preferred stock warrant liability during the period were recorded as a component of other expense, net, in the consolidated statements of operations. Derivative Liability The Company has a derivative liability related to the contingent consideration associated with the acquisition of InteKrin. There were two contingent payments payable upon the achievement of certain events: (i) the completion of the first dosing of a human subject in the first Phase 2 clinical trial for InteKrin, (“Earn-Out Payment”) and (ii) upon the execution of any license, sublicense, development, collaboration, joint venture, partnering or similar agreement between the Company and the third party (“Compound Transaction Payment”). The derivative related to the contingent consideration is accounted for as a liability and remeasured to fair value as of each balance sheet date and the related remeasurement adjustment is recognized as other income (expense), net in the consolidated statements of operations. The Company determined the fair value of the two contingent consideration scenarios (the Earn-Out Payment and the Compound Transaction Payment) using a probability-weighted discounted cash flow approach. A probability-weighted value was determined by summing the probability of achieving a contingent payment threshold by the respective contingent payments. The expected cash flows were discounted at a rate selected to capture the risk of achieving the contingent payment thresholds and earning the contingent payment. This risk is comprised of InteKrin’s continued development, a specific risk factor associated with meeting the contingent consideration threshold and related payout, and counterparty risk associated with the payment of the contingent consideration. Embedded Derivative Liability The Company recorded derivative instruments related to redemption features embedded within the convertible notes when such notes were outstanding. The embedded derivatives were accounted for as a liability and were remeasured to fair value as of each balance sheet date when such notes were outstanding, with the related remeasurement adjustment being recognized as a component of other income (expense), net in the consolidated statements of operations. Accrued Research and Development Expenses Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research organizations and clinical sites. The Company determines the actual costs through monitoring patient enrollment, discussions with internal personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. Revenue Recognition The Company recognizes revenue when persuasive evidence of an arrangement exists; transfer of technology has been completed, services have been performed or products have been delivered; the fee is fixed and determinable; and collection is reasonably assured. For revenue agreements with multiple elements, the Company identifies the deliverables included within the agreement and evaluates which deliverables may represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. Deliverables under the arrangement are a separate unit of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item and delivery or performance of the undelivered items are considered probable and substantially within the Company’s control. The Company determines how to allocate arrangement consideration to identified units of accounting based on the selling price hierarchy provided under the relevant guidance. The selling price used for each unit of accounting is based on vendor-specific objective evidence, if available, third party evidence if vendor-specific objective evidence is not available or estimated selling price if neither vendor-specific nor third-party evidence is available. Management may be required to exercise considerable judgment in determining whether a deliverable is a separate unit of accounting and in estimating the selling prices of identified units of accounting under its agreements. Upfront payments received in connection with licenses of the Company’s technology rights are deferred if facts and circumstances dictate that the license does not have stand-alone value. Such payments are recognized as license revenue over the estimated period of performance that is generally consistent with the terms of the research and development obligations contained in the specific collaboration and license agreement. The Company regularly reviews the estimated period of performance based on the progress made under each arrangement. Amounts received as funding of research and development activities are recognized as revenue if the collaboration arrangement involves the sale of the Company’s research or development services. However, such funding is recognized as a reduction in research and development expense when the Company engages in a research and development project jointly with another entity, with both entities participating in project activities and sharing costs and potential benefits of the arrangement. Payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved, assuming all other revenue recognition criteria are met. A milestones is defined as an event that can only be achieved based on the Company’s performance where there is substantive uncertainty about whether the event will be achieved at the inception of the arrangement. Events that are contingent only on the passage of time or only on counterparty performance are not considered milestones under accounting guidance. The Company’s evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the Company’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the Company’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Other contingent payments in which a portion of the payment is refundable or adjusts based on future performance or non-performance (e.g., through a penalty or claw-back provision) are not considered to relate solely to the Company’s past performance, and therefore, not considered substantive. Non-substantive contingent payments are classified as deferred revenue if they are ultimately expected to result in revenue recognition. The Company recognizes non-substantive contingent payments over the remaining estimated period of performance once the specific objective is achieved. Any portion of the non-substantive contingent payments which may be required to be refunded to the collaborator are not included in deferred revenue and instead are reflected as contingent liability to collaborator on the consolidated balance sheets. Contingent payments associated with the achievement of specific objectives in certain contracts that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are recognized as revenue upon achievement of the objective, as long as there are no undelivered elements remaining and no continuing performance obligations by the Company, assuming all other revenue recognition criteria are met. Revenue from a government contract is recognized in the period during which the related costs are incurred and the related services are rendered, provided that the funds received are not refundable and applicable conditions under the government contract have been met. Funds received in advance are recorded as deferred revenue. Research and Development Expenses Research and development costs are charged to expenses as incurred. Research and development expenses include, among other costs, salaries and other personnel-related costs, consultant fees, preclinical costs, cost to manufacture drug candidates and clinical supplies, laboratory supplies costs and facility-related costs. Costs incurred under agreements with third parties are charged to expense as incurred in accordance with the specific contractual performance terms of such agreements. Costs of third parties include costs associated with preclinical and clinical support activities. In certain cases, amounts received as reimbursement of research and development activities from the Company’s collaborators are recognized as a reduction in research and development expense when the Company engages in a research and development project jointly with another party, with both parties incurring costs while actively participating in project activities and both parties sharing costs and potential benefits of the arrangement. Costs incurred under the arrangements where the Company provides research services approximate the amount of revenues recorded. Advance payments for goods or services to be received in the future to be utilized in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are received. Stock-Based Compensation The Company measures the cost of equity-based service awards based on the grant-date fair value of the award, and recognizes the cost of such awards straight-line over the vesting period. Because non-cash stock compensation expense is based on awards ultimately expected to vest, it is reduced by an estimate for future forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. The Company accounts for equity instruments issued to nonemployees using the fair value approach. These equity instruments consist of stock options and restricted common stock, which are valued using the Black-Scholes option-pricing model. Stock-based compensation expense is recognized as the equity instruments are earned. The measurement of stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest. The Company utilizes the Black-Scholes option-pricing model for estimating fair value of its stock options and restricted stock granted. Option valuation models, including the Black-Scholes option-pricing model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, the expected life of the award, and estimated forfeitures. Income Taxes The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had accrued no amounts for interest and penalties related to income tax matters in the Company’s consolidated balance sheets at December 31, 2015 and 2014. Comprehensive Loss Comprehensive loss is composed of two components: net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity, but are excluded from net loss. The Company’s other comprehensive loss included foreign currency translation adjustments for the years ended December 31, 2015 and 2014. Net Loss per Share Attributable to Coherus Basic net loss per share attributable to Coherus is calculated by dividing the net loss attributable to Coherus by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common shares. Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Coherus is the same as diluted net loss per share attributable to Coherus as the inclusion of all potential dilutive common shares would have been anti-dilutive for all periods presented. Shares of founders’ common stock subject to repurchase are excluded from the calculation of weighted average shares as the vesting of such shares is contingent upon continued services being rendered by such holders. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers: Deferral of the Effective Date , the FASB deferred the effective date of ASU 2014-09 for public business entities to fiscal years beginning after December 15, 2017, including interim reporting periods within that reporting period, with early adoption permitted on the original effective date of fiscal years beginning after December 15, 2016 In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern all annual and interim reporting periods thereafter, In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes all annual and interim reporting periods thereafter, In January 2016, the FASB issued ASU No. 2016-1, Recognition and Measurement of Financial Assets and Financial Liabilities. all annual and interim reporting periods thereafter. E In February 2016, the FASB issued ASU No. 2016-2, Leases The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or no material effect is expected on the consolidated financial statements as a result of future adoption.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements Financial assets and liabilities are recorded at fair value. The carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and other current liabilities approximate their fair value due to their short maturities. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The accounting guidance describes a fair value hierarchy based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable. These levels of inputs are the following: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of Level 1 assets and Level 3 liabilities. Where quoted prices are available in an active market, securities are classified as Level 1. Level 1 assets consist of highly liquid money market funds that are included in cash and cash equivalents, and restricted cash. There were no unrealized gains and losses in the Company’s investments in these money market funds. In certain cases where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3. Level 3 liabilities consist of the contingent consideration. Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements are as follows (in thousands): Fair Value Measurements December 31, 2015 Total Level 1 Level 2 Level 3 Assets: Money market funds $ 157,784 $ 157,784 $ — $ — Restricted cash (money market funds) 845 845 — — Total financial assets $ 158,629 $ 158,629 $ — $ — Liabilities: Contingent consideration $ 1,245 $ — $ — $ 1,245 Fair Value Measurements December 31, 2014 Total Level 1 Level 2 Level 3 Assets: Money market funds $ 147,952 $ 147,952 $ — $ — Restricted cash (money market funds) 60 60 — — Total financial assets $ 148,012 $ 148,012 $ — $ — Liabilities: Contingent consideration $ 6,495 $ — $ — $ 6,495 There were no transfers between Level 1 and Level 3 during the periods presented. Contingent Consideration As part of the InteKrin acquisition, the Company recognized contingent consideration associated with potential payments to be made to the former InteKrin stockholders upon the achievement of certain events specified in the agreements (see Note 6). This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The InteKrin purchase agreement provides for contingent consideration to be paid upon (i) the first dosing of a human subject in the first Phase 2 Clinical Trial for CHS-131 (formerly INT-131) ("Earn-Out Payment") and (ii) per a compound transaction agreement as defined in the purchase agreement (the “Compound Transaction Payment”). The Company valued the two contingent consideration scenarios (the Earn-Out Payment and the Compound Transaction Payment) using a probability-weighted discounted cash flow approach. A probability of reaching each contingent consideration threshold was estimated by Company’s management. As of December 31, 2014, the Earn-Out Payment was expected to occur in January 2015 with a 98% probability of occurrence. As part of that analysis, a 25% risk-adjusted discount rate was used to measure a present value. A separate credit spread was not applied to the Earn-Out Payment fair value since the consideration was to be made in common stock shares. The size of the contingent consideration was a fixed number of common stock shares, but the value fluctuated with the value of a common stock share. The Compound Transaction applied the same 25% risk-adjusted discount rate and also captured an additional 6% credit spread for counterparty credit risk given the cash payment. The Company’s management estimates of probability of occurrence and timing were used to formulate an expected cash flow. The size of the consideration is tiered based on the size of a license or similar agreement with a third party and the timing of such agreement. The change in the fair value of the contingent consideration liability is recognized in other expense, net within the consolidated statement of operations. On March 6, 2015, the Company achieved the first dosing of a human subject in a phase 2 clinical trial for CHS-131 in multiple sclerosis patients, triggering the obligation to settle the first contingent Earn-Out Payment to former InteKrin stockholders. As a result, the Company issued 358,384 shares of its common stock valued at $27.48 per share and cash of $1,000 for the aggregate amount value of $9.8 million to former InteKrin stockholders. Contemporaneously, the Company recognized the additional fair value of the Earn-Out Payment of $4.1 million to other expense, net, in the consolidated statement of operations on March 6, 2015 and reclassified the contingent consideration liability balance to equity in the consolidated balance sheet. For the years ended December 31, 2015 and 2014, the Company recognized $4.1 million and $5.0 million, respectively, in other expense, net in the consolidated statement of operations for the change in the fair value of the Earn-Out Payment. The fair value measurement of the Compound Transaction Payment uses a probability-weighted discounted cash flow approach based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The Compound Transaction analysis applied a 25% risk-adjusted discount rate to measure present value and also captured an additional 6% credit spread for counterparty credit risk given the cash payment. The Company’s management estimates of probability of occurrence and timing were used to formulate an expected cash flow. The value of the consideration is tiered based on the value of a license or similar agreement with a third party and the timing of such agreement. The change in the fair value of the Compound Transaction Payment was recognized in other expense, net in the consolidated statement of operations of $460,000 and $235,000 for the years ended December 31, 2015 and 2014, respectively. The following table sets forth a summary of changes in the estimated fair value of the contingent consideration (in thousands): Balance as of February 12, 2014 (acquisition date) $ 1,310 Change in fair value of the contingent consideration liability 5,185 Balance as of December 31, 2014 6,495 Change in fair value of the contingent consideration liability 4,599 Fair value of Earn-Out Payment settled in common stock on March 6, 2015 (9,849 ) Balance as of December 31, 2015 $ 1,245

Balance Sheet Components

Balance Sheet Components	12 Months Ended
	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Components	4. Balance Sheet Components Prepaid Assets Prepaid assets are as follows (in thousands): December 31, December 31, 2015 2014 Prepaid clinical, material, manufacturing and other - related parties (see Note 15) $ 10,901 $ 5,990 Prepaid clinical, material and manufacturing 21,191 12,149 Prepaid other 2,651 2,346 Prepaid assets $ 34,743 $ 20,485 Property and Equipment, Net Property and equipment, net are as follows (in thousands): December 31, December 31, 2015 2014 Machinery and equipment $ 7,809 $ 4,317 Computer equipment and software 1,276 286 Furniture and fixtures 596 288 Leasehold improvements 4,343 399 Construction in progress — 474 Total property and equipment 14,024 5,764 Accumulated depreciation and amortization (3,520 ) (1,292 ) Property and equipment, net $ 10,504 $ 4,472 Depreciation expense was $1.9 million, $674,000 and $404,000 for the years ended December 31, 2015, 2014 and 2013, respectively. In July 2015, the Company entered into a new lease agreement with its landlord for its new headquarters facility in Redwood City, California (see Note 6). The Company moved into the new facility in December 2015 and recorded $3.1 million in leasehold improvements related to the new headquarters. Accrued Liabilities Accrued liabilities are as follows (in thousands): December 31, December 31, 2015 2014 Accrued clinical, manufacturing and other - related parties (see Note 15) $ 6,122 $ 2,997 Accrued clinical and manufacturing 11,681 2,396 Accrued compensation 4,666 3,435 Accrued professional and consulting fees 446 252 Accrued other 1,218 2,151 Accrued liabilities $ 24,133 $ 11,231

Collaboration and License Agree

Collaboration and License Agreement	12 Months Ended
	Dec. 31, 2015
Collaboration And License Agreements [Abstract]
Collaborative and License Agreement	5. Collaboration and License Agreement The Company recognized revenue related to the collaboration and license agreements for the periods presented as follows (in thousands): Year Ended December 31, 2015 2014 2013 Baxalta $ 27,802 $ 28,481 $ 726 Daiichi Sankyo - related party (1) 2,239 1,893 2,025 Total collaboration and license revenue $ 30,041 $ 30,374 $ 2,751 (1) Represents revenue from Daiichi Sankyo through November 12, 2014 as a related party, a holder of more than 10% of our common stock until the closing of our initial public offering (“IPO”). Daiichi Sankyo In January 2012, the Company entered into a license agreement with Daiichi Sankyo, under which the Company granted certain licenses to Daiichi Sankyo to develop and commercialize biosimilar forms of etanercept and rituximab in Japan, Taiwan, and South Korea with an option to develop in China. Under the terms of the agreement, the Company will be responsible for the manufacturing and supply of the products during the development activities and Daiichi Sankyo will conduct the development, regulatory approval filings, and commercialization activities of the biosimilar form of etanercept and rituximab products in Japan. Once the biosimilar forms of etanercept and rituximab are commercialized, the Company is entitled to royalties based on net sales by Daiichi Sankyo on a product-by-product basis in the licensed territories ranging from the low double digits to high teens, on a product-by-product basis. If the Company is manufacturing product, the Company is eligible to receive an incremental royalty reflecting the manufacturing costs for each licensed product which, when combined with the base royalty, will result in royalties equal to a percentage of net sales of licensed products ranging from the low to high-twenties, on a product-by-product basis. Upon execution of the agreement, Daiichi Sankyo paid a non-refundable, upfront license fee of $10.0 million and purchased 2,867,426 shares of Series B convertible preferred stock at a price of $6.9749 per share, or $18.1 million in net cash proceeds. The Company concluded that there was no premium or discount associated with the purchase of the Series B convertible preferred stock since Daiichi Sankyo paid the same price paid by other investors at the close of the Series B convertible preferred stock offering. As such the Company recorded the $18.1 million as a convertible preferred stock transaction separate from the license agreement. The agreement has an initial term of ten years and contains provisions allowing Daiichi Sankyo to renew the agreement for an additional three years with respect to particular countries. Daiichi Sankyo also has the right to terminate the agreement, in its entirety or on a country-by country basis, at any time if the development and/or commercialization is deemed to not be commercially viable, there are material safety, efficacy or patient tolerability issues that cannot be remedied or overcome, or during the opt-out window after the achievement of specified objectives in the agreement. In May 2012, Daiichi Sankyo opted out of the development and commercialization of etanercept in Taiwan and South Korea, and in August 2012, Daiichi Sankyo chose not to exercise their option with respect to the development and commercialization of etanercept and rituximab in China. The Company identified the following deliverables under the agreement: (1) the transfer of intellectual property rights (license), and (2) the manufacture of drug materials for clinical development purposes. The Company considered the provisions of the multiple-element arrangement guidance in determining how to recognize the total consideration of the agreement. The Company has concluded that the license is not a separate unit of accounting because Daiichi Sankyo cannot obtain benefit from the use of the license rights for their intended purpose without the products manufactured by the Company. Daiichi Sankyo must rely upon the Company to manufacture and supply the products necessary for Daiichi Sankyo’s development because the related manufacturing know-how specific to the products is proprietary to the Company and Daiichi Sankyo does not have the right to manufacture the licensed product. The Company determined that neither of the deliverables have standalone value and, therefore, the deliverables are accounted for as a single unit of accounting with the upfront fee recognized as revenue on a straight-line basis over its estimated period of performance of approximately three years. The Company determined that there is no other method that is more appropriate than the straight-line method of revenue recognition for this agreement given there is no discernable pattern of its performance under the arrangement. The Company regularly evaluates the reasonableness of the estimated period of performance and revises the amortization of deferred revenue as deemed appropriate on a prospective basis. On September 30, 2014 and December 31, 2014, the Company extended the period of performance for two quarters and one quarter, respectively, through the fourth quarter of 2017. On September 2015, the Company revised the period of performance extending the period to November 2017. In June 2013, the Company and Daiichi entered into a Memorandum of Understanding No. 1 (the “MOU 1”) in which both parties agreed to cooperate and share costs to conduct a global Phase 1 study of a biosimilar form of etanercept. This program was not originally contemplated in the license agreement. Under the MOU 1, the Company will gather all clinical data, format it into a case study report, and conduct the final analysis. The Company will transfer the clinical data and other regulatory approval application documents for the product and post marketing to Daiichi Sankyo within 90 days after such documents are finalized. Under the MOU 1, Daiichi’s Sankyo’s overall cost sharing responsibility include (i) 33% of the total budgeted cost and (ii) 100% of the cost of the comparator drug (Enbrel) used for the Japanese volunteers. The amounts received from Daiichi Sankyo under this cost sharing responsibility are recognized as a reduction in research and development expense as the Company engages in a research and development project jointly with Daiichi Sankyo, with both parties incurring costs while actively participating in development activities and both parties sharing costs and potential benefits of the arrangement. The Company accounted for the MOU 1 as a separate arrangement which was not deemed to be a material modification of the original license agreement with Daiichi Sankyo. In January 2014, the Company and Daiichi Sankyo entered into the Memorandum of Understanding No. 2 (the “MOU 2”) in which both parties agreed to cooperate to conduct a global Phase 3 clinical trial in rheumatoid arthritis and that Daiichi Sankyo will be responsible for a minimum of 20% of the cost of the clinical trial. Also, both parties entered into a clinical supply agreement contemporaneously with the MOU 2 in which the Company will supply finished study drug and study comparator drug for Daiichi Sankyo’s use in the Japanese portion of the product’s clinical trial. Daiichi Sankyo reimburses these research and development costs in quarterly advance payments, for which the Company recorded $1.3 million and $1.2 million as advance payments under license agreement in the consolidated balance sheet as of December 31, 2015 and 2014, respectively. The Company will recognize the advance payment as a reduction in the research and development expense when the research and development activity has been performed. In June 2015, the Company and Daiichi Sankyo entered into the Memorandum of Understanding No. 3 (the “MOU 3”) in which both parties agreed to cooperate further on a global Phase 3 clinical trial in rheumatoid arthritis. Under the MOU 3, Daiichi Sankyo will be responsible for a minimum of 20% of the cost of an open label, safety extension study (“OLSES”) in rheumatoid arthritis. The Company also entered into a clinical supply agreement as part of the MOU 3 in which the Company will supply finished study drug and study comparator drug for Daiichi Sankyo’s use in the Japanese portion of the clinical trial. Daiichi Sankyo will pre-pay these research and development costs quarterly, and they are recorded by the Company as advance payments in the consolidated balance sheet. The Company recognizes the advance payments as a reduction of research and development expense when the research and development activity has been performed. As of December 31, 2015, $2.8 million of revenue was deferred under all arrangements with Daiichi Sankyo, of which $1.5 million was included in current liabilities and $1.3 million was included in non-current liabilities in the consolidated balance sheet. As of December 31, 2014, $4.3 million of revenue was deferred under all arrangements with Daiichi Sankyo, of which $1.6 million was included in current liabilities and $2.7 million was included in non-current liabilities in the consolidated balance sheet. The Company recognized in its consolidated statements of operations a reduction of research and development expense related to the costs reimbursed by Daiichi Sankyo of $16.1 million, $7.1 million and $1.3 million for the years ended December 31, 2015, 2014 and 2013, respectively. Baxalta In August 2013, the Company entered into a license agreement with Baxter, to develop and commercialize an etanercept biosimilar molecule, CHS-0214, worldwide, excluding the United States, Japan, Taiwan, South Korea, China and most of the Caribbean and South American nations. In the second quarter of 2015, Baxter assigned its rights and obligations under the license agreement to affiliated entities that are under common control of Baxalta. Under the terms of the license agreement, the Company will conduct the development and the regulatory activities, and Baxalta will conduct the commercialization of the etanercept biosimilar product. Under the terms of the agreement, the Company will conduct the development and the regulatory activities, and Baxalta will conduct the commercialization of the etanercept biosimilar product. In consideration of the exclusive, royalty-bearing license to develop, commercialize and use the etanercept biosimilar product, Baxalta made an upfront payment of $30.0 million to the Company. Additionally, the Company is eligible to receive up to $216.0 million in contingent payments composed of $96.0 million in clinical development payments and up to $120.0 million in regulatory milestone payments. If the cumulative development costs exceed the cumulative contingent payments, Baxalta will reimburse the Company for the excess cost as set forth in the agreement up to predetermined limits. Once the etanercept biosimilar product is commercialized, the Company is entitled to tiered royalties, based on the manufacturing cost as a percentage of net sales of licensed products, ranging from the mid-single digits to the high teens on a country-by-country basis. These royalties are subject to certain offsets and reductions. The agreement has an initial term of ten years and contains provisions allowing Baxalta to renew the agreement for another three years on a country-by-country basis. Baxalta also has the right to terminate the agreement, in its entirety or on a country-by country basis, at any time if the development and/or commercialization is deemed to not be commercially viable, there are material safety, efficacy or patient tolerability issues that cannot be remedied or overcome, if aggregate expenses exceed certain thresholds or after the first commercial sale upon 18 month prior written notice. The Company identified the following deliverables under the license agreement with Baxalta: 1) the transfer of intellectual property rights (license), (2) the obligation to provide research and development services including the manufacturing and supply of clinical product, and (3) the obligation to participate on various committees. The Company considered the provisions of the multiple-element arrangement guidance in determining how to recognize the total consideration of the agreement. The Company determined that the license does not have standalone value to Baxalta without the Company’s technical expertise as it relates to the development of the product candidate and committee participation. Additionally, the license to Baxalta does not include the right to manufacture, or have manufactured the product during the development stage, or to conduct any process development activities. Therefore, the Company concluded that these deliverables represent a single unit of accounting under the multiple-element arrangement guidance. The upfront payment of $30.0 million and clinical development payments of up to $96.0 million include $56.0 million of contingent payments that are intended to cover development related expenses incurred by the Company, but potentially reimbursable, in part, to Baxalta under certain limited circumstances. The Company concluded that the contingent payments that contain potentially reimbursable amounts to Baxalta are not substantive milestones under the relevant accounting guidance, since the guidance does not allow the substantive milestone components of a payment to be bifurcated from non-substantive milestone components. The amounts that are contingent payments also contain a claw-back feature that, in the event that the Company commercializes the etanercept biosimilar molecule in the U.S. without Baxalta, fifty percent (50%) of those contingent payments are refundable to Baxalta. Therefore, the Company will record the portion of the non-substantive contingent payment that contains the claw-back feature as a liability for the potential reimbursement of such funds to Baxalta until the earlier of: (1) expiration or termination of the license agreement, which is ten years, or (2) the determination of the party to commercialize the molecule in the U.S. These amounts are included in the contingent liability to collaborator on the consolidated balance sheets. The portion of the non-substantive milestone payment that does not contain the claw-back feature will be recorded as deferred revenue and recognized as license revenue on a straight-line basis over the remaining estimated performance period of approximately three years. The Company determined that there is no other method that is more appropriate than the straight-line method of revenue recognition for this agreement given there is no discernable pattern of performance under the arrangement. The Company regularly evaluates the reasonableness of the estimated period of performance and revises the amortization of deferred revenue as deemed appropriate on a prospective basis. On September 30, 2014 and December 31, 2014, the Company revised the period of performance extending the period of performance for two quarters and one quarter, respectively. On September 2015, the Company revised the period of performance extending the period to November 2017. The $120.0 million of regulatory milestone payments are considered substantive as the achievement is subject to the significant uncertainty as to the outcome of the development efforts, by the Company, over an extended period of time, and the Company’s substantive performance obligation under the license agreement which includes efforts associated with the clinical trials and filing and approval of drug applications by regulatory authorities in various countries. Therefore, the Company will recognize revenue associated with these respective contingent payments when each of the specific events is achieved. In February 2014, the agreement was amended to increase the payment by $5.3 million therefore the Company is eligible to receive up to $221.3 million in contingent payments comprised of $101.3 million in clinical development payments, and up to $120.0 million in regulatory milestone payments. In April 2015, the Company and Baxalta, entered into a second amendment (the “Second Amendment”) to the license agreement. Under the terms of the Second Amendment, a revised milestone payment structure totaling $130.0 million replaced certain existing milestone and funding obligations under the license agreement as originally executed. Therefore the Company is eligible to receive up to $335.3 million in contingent payments comprised of $215.3 million in clinical development payments, and up to $120.0 million in regulatory milestone payments. The Second Amendment does not provide for any change in the contracted deliverables set forth in the license agreement. As a result, the original assessment of the standalone value for the deliverables remains unchanged and the deferred revenue previously recorded prior to the Second Amendment continues to be recognized as revenue on a straight-line basis over the remaining expected performance period. Likewise, the contingent liability from the incremental milestones received under the license agreement prior to Second Amendment has not been adjusted. If the Company commercializes CHS-0214, its etanercept biosimilar product, in the United States, the Company will be required to refund a portion of the milestone payments received from Baxalta as specified in the Second Amendment. A portion of each of the $130.0 million milestones would be subject to refund. The Company concluded that the payments that contain potentially reimbursable amounts to Baxalta are not substantive milestones under the relevant accounting guidance, since the guidance does not allow the substantive milestone components of a payment to be bifurcated from non-substantive milestone components. Therefore, the Company will record the portion of the contingent payment that contains the claw-back feature as a liability for the potential reimbursement of such funds to Baxalta until the earlier to occur of: (1) expiration of the license agreement pursuant to its terms in August 2023, (2) the earlier termination of the license agreement, or (3) the determination, pursuant to the terms of the license agreement, of the third party to commercialize CHS-0214 in the U.S. This liability is included in the contingent liability to collaborator on the consolidated balance sheets. The portion of the milestone payment that does not contain the claw-back feature will be recorded as deferred revenue and recognized as license revenue on a straight-line basis over the remaining estimated performance period as there is no discernable pattern of performance under the arrangement. Pursuant to the Second Amendment, the Company received a total of $100 million in milestone payments in 2015 which The Second Amendment provides that Baxalta would purchase $10.0 million of the Company’s common stock. As a result, on September 10, 2015, the Company sold Baxalta an aggregate of 390,167 shares of common stock at $25.63 per share (the fair value of the common stock on the day of pricing, September 9, 2015) for aggregate gross proceeds of approximately $10.0 million (see Note 11). As of December 31, 2015, $92.0 million of revenue was deferred under the arrangements with Baxalta, of which $48.0 million was included in current liabilities and $44.0 million was included in non-current liabilities in the consolidated balance sheet. As of December 31, 2015, $66.3 million was recorded as contingent liability to collaborator in the consolidated balance sheet due to the potential refund to Baxalta. As of December 31, 2014, $58.4 million of revenue was deferred under the arrangements with Baxalta, of which $21.2 million was included in current liabilities and $37.2 million was included in non-current liabilities in the consolidated balance sheet. As of December 31, 2014, $27.7 million was recorded as contingent liability to collaborator due to the potential refund of such amount to Baxalta in the future. Additionally in 2014, the Company received $10.0 million for the achievement of a substantive milestone pursuant to the license agreement and accordingly recognized the entire amount as collaboration and license revenue in its consolidated statements of operations in the third quarter of 2014.

Acquisition of InteKrin Therape

Acquisition of InteKrin Therapeutics, Inc.	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Acquisition of InteKrin Therapeutics, Inc.	6. Acquisition of InteKrin Therapeutics Inc. On January 8, 2014, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) to acquire all of the outstanding shares of InteKrin and its 82.5% majority owned subsidiary, InteKrin Russia. On February 12, 2014, the Company completed the acquisition of InteKrin (the “Merger”) for total consideration of $5.0 million. The acquisition was a related party transaction (see Note 15). Prior to the Merger, InteKrin was a privately held, clinical-stage biopharmaceutical company focused on the development and commercialization of novel drugs for the treatment of immune diseases such as multiple sclerosis. InteKrin’s primary product candidate is CHS-131, which is in the clinical stage of development. Although CHS-131 is a small molecule and not a protein, its therapeutic focus area was complementary to the Company’s emerging multiple sclerosis biosimilar product pipeline which consists of broader level, central nervous system anti-inflammatory drug candidates. This in turn was complementary to the Company’s systemic focus on anti-inflammatory drug candidates with the anti-tumor necrosis factor (TNF) portfolio composed of etanercept and adalimumab biosimilars. Additionally, the acquisition of InteKrin was a strategic transaction to obtain funding from new investors. The Company accounted for the InteKrin acquisition as the purchase of a business. The Company expensed the related acquisition costs, consisting primarily of legal expenses in the amount of $134,000. These legal expenses are recorded in general and administrative expense in the consolidated statement of operations for the year ended December 31, 2014. The total consideration of $5.0 million consists of: (a) issuance of 716,645 shares of Series B preferred stock with a fair value of $2.7 million, (b) assumption of InteKrin’s convertible promissory note payable to an InteKrin stockholder, which was concurrently paid off by issuing 243,841 shares of the Company’s Series B convertible preferred stock with a fair value of $1.0 million (c) cash payment of $1,485, and (d) contingent consideration of $1.3 million. The Company determined the fair value of the Series B convertible preferred stock of $3.8174 per share using the PWERM. The non-controlling interest was not deemed to be significant at acquisition. Pro forma results of operations for this acquisition have not been presented as such results are not material to the Company’s results of operations for the years ended December 31, 2014 and 2013. The following table summarizes the original fair value of the assets acquired and liabilities assumed (in thousands): Cash $ 2,335 Prepaid and other assets 107 Accounts payable and other current liabilities (1,027 ) In-process research and development 2,620 Goodwill 943 Total $ 4,978 In connection with the acquisition of InteKrin, the Company recorded a deferred tax liability related to the acquired in-process research and development. This deferred tax liability represents a new source of future taxable income, which required the release of a portion of InteKrin’s deferred tax asset valuation allowance equal to the deferred tax liability recorded. The deferred tax asset and liability are both classified as long term for purposes of the balance sheet presentation. Intangible Asset — In-process Research and Development The in-process research and development (“IPR&D”) consists of InteKrin’s CHS-131. The Company determined the fair value of the IPR&D based on the cost to recreate the asset to its current stage as the fair value is not determinable as a result of the lack of financial projections for this asset due to its early development stage. By applying this method, management estimated that $2.6 million of the acquisition consideration represents the fair value of the IPR&D. The IPR&D acquired through the InteKrin acquisition is treated as an indefinite-lived intangible asset and an annual impairment review is performed by management. As of December 31, 2015, there has been no impairment of this IPR&D. Contingent Consideration The contingent consideration is made up of two potential payments as discussed below. Contingent Consideration — Earn-Out Payment: Upon completion of the first dosing of a human subject in the first Phase 2 clinical trial for InteKrin, InteKrin’s stockholders could earn a minimal cash payment and 358,384 shares of the Company’s Series B convertible preferred stock upon the successful achievement of this objective. At the acquisition date, the Company expected the first dosing to be completed in September 2014 and assigned a 75% success probability to the achievement and timing of this event. As such, at the acquisition date, the fair value of the contingent consideration related to this earn-out payment was determined to be $0.8 million. As of the consummation of the IPO in November 2014, such contingent consideration was payable by issuing shares of common stock rather than shares of Series B convertible preferred stock. C ontingent Consideration — Compound Transaction Payment: At the time of the acquisition, the Company estimated that the probability of achieving the compound transaction agreement event was 7.5% of the fair value of this contingent consideration based on a probability weighted determination of both the range of the amount and the likelihood of achieving the estimated payouts. At the acquisition date, the fair value of this contingent consideration from the compound transaction payment was determined to be $0.5 million. At the acquisition date, the Company valued the two contingent consideration scenarios using a probability-weighted discounted cash flow approach. A probability of reaching each contingent consideration threshold was estimated by management. A probability-weighted value was determined by multiplying the probability of achieving a contingent payment threshold by the respective contingent payment. The expected cash flows were discounted at a rate selected to capture the risk of achieving the contingent payment thresholds and earning the contingent payment. This risk is composed of InteKrin’s continued development, a specific risk factor associated with meeting the contingent consideration threshold and related payout and counterparty risk associated with the payment of the contingent consideration. As of December 31, 2014, the fair value of this contingent consideration liability increased to $6.5 million to reflect the updated fair value estimate of the liability and accordingly $5.2 million was recognized as an expense in the consolidated statement of operations during year ended December 31, 2014. The increase in the updated fair value of the contingent consideration is due to changes in the Company’s estimate of reaching each contingent consideration threshold and the increase in the fair value of the Company’s common stock (see Note 3). On March 6, 2015, the Company achieved the first dosing of a human subject in a phase 2 clinical trial for CHS-131 in multiple sclerosis patients, triggering the obligation to settle the contingent Earn-Out Payment to former InteKrin stockholders. As a result, the Company issued 358,384 shares of its common stock valued at $27.48 per share and cash of $1,000 for the aggregate amount value of $9.8 million to former InteKrin stockholders (see Note 3). As of December 31, 2015, the fair value of this contingent consideration liability decreased to $1.2 million to reflect the Earn-Out Payment settlement in March 2015 and the updated fair value estimate of the Compound Transaction Payment. Accordingly $4.6 million was recognized as an expense in the consolidated statement of operations during the year ended December 31, 2015 (see Note 3). Goodwill Goodwill resulting from this acquisition comprises the excess of the purchase price over the fair value of the underlying net assets acquired and primarily represents the strategic relationship acquired with InteKrin’s investors. None of this goodwill will be deductible for tax purposes. Under the applicable accounting guidance, goodwill will not be amortized but will be tested for impairment on an annual basis or more frequently if certain indicators are present. As of December 31, 2015, there have been no such impairments. Government Contract with the Russian Government In 2012, InteKrin Russia, a subsidiary of InteKrin, was awarded a contract by the Ministry of Industry and Trade of the Russian Federation to perform scientific research and experimental development work for the treatment of multiple sclerosis and conducting its preclinical and clinical studies for a total aggregate amount of 147.9 million RUB ($2.6 million in US dollars as of December 31, 2014) which was expanded multiple years from 2012 to 2015. The contract amount related to the 2014 research period was expected to be 40.0 million RUB. Subsequent to the Company’s acquisition of InteKrin in February 2014, the Company received 12.0 million RUB and 28.0 million RUB in the first and fourth quarter of 2014, respectively. These advance receipts of funding were deferred until the Company met all the revenue recognition criteria in 2014. The Company recognized revenue of 40.0 million RUB ($732,000 based on the exchange rate on the date the revenue was recognized) as other revenue in the consolidated statement of operations for the year ended December 31, 2014. The remaining amount available under the government contract for 2015 is 39.4 million RUB, of which 11.8 million RUB ($162,000) was received in the first quarter of 2015 and reflected as deferred revenue in the consolidated balance sheet as of December 31, 2015.

Debt Obligations

Debt Obligations	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt Obligations	7. Debt Obligations From July 2013 to September 2013, the Company entered into convertible note agreements (the “Bridge Loans”) with various stockholders, employees and institutions for an aggregate principal amount of $10.0 million. The Bridge Loans accrued interest of 8% per annum and would mature on July 15, 2014. The principal and the accrued interest on the Bridge Loans were converted into 5,488,892 shares of Series C convertible preferred stock in May 2014 (see note 11). In connection with the Bridge Loans, the Company also issued warrants to purchase shares of its convertible preferred stock at an exercise price of $0.0167 per share. The determination of the number of shares issuable pursuant to the 2013 warrants was determined based on 300% of the principal amount of the Bridge Loans divided by the conversion price. In addition, at the issuance date of the notes, there was a beneficial conversion feature. The total aggregate Bridge Loans of $10.0 million were less than the initial fair value of the warrants of $13.6 million at the issuance date. Therefore $10.0 million was recognized as debt discount, and the difference of $3.6 million was immediately charged to other income (expense), net in the consolidated statement of operations and comprehensive loss as the carrying value of the debt could not be reduced to less than zero. No value was recorded initially for the beneficial conversion feature since the carrying value of the debt was zero. The debt discount of $10.0 million was accreted using the effective interest method as an additional interest expense over the term of the Bridge Loans. The Bridge Loans redemption features were determined to be embedded derivatives requiring bifurcation and separate accounting. The fair value of the embedded derivative liability at issuance was determined to be $4.1 million. As a result of the fair value of the warrant debt discount reducing the debt to zero at the time of the issuance as discussed above, the estimated fair value of the derivative liability of $4.1 million was recognized within other income (expense), net, in the consolidated statement of operations and comprehensive loss and as a derivative liability on the consolidated balance sheet upon issuance. Changes in the fair value of the embedded derivative have also been recorded within other income (expense), net, in the consolidated statement of operations and comprehensive loss. The Company periodically remeasured the derivative liability to fair value. In December 2013, following the receipt of the upfront license payment from Baxalta license agreement (see Note 5), the Company met the qualified licensing threshold (“QLT”). As a result, upon a change of control, a redemption feature related to the holders’ option to receive a cash payment in lieu of conversion into Series B convertible preferred stock was reduced from 400% to 100% of the outstanding principal, plus accrued interest and the associated embedded derivative liability was reduced to zero. The Bridge Loans were collateralized by a security interest in all assets, tangible and intangible, of the Company, subject to a prior security interest of Cook on the Company’s property and equipment in Camarillo, California. Upon the issuance of Series C convertible preferred stock in May 2014, all security interests to the Company’s asserts, tangible and intangible, were released. In May 2014, the Company completed an equity financing of Series C convertible preferred stock and, as a result, the Bridge Loans and related accrued interest of $10.6 million automatically converted into 1,058,089 shares of Series C convertible preferred stock based on the price per share paid by other investors in the financing. In connection with the extinguishment of the Bridge Loans, the Company reacquired the beneficial conversion feature. The intrinsic value of the beneficial conversion feature at the date of the Bridge Loans extinguishment was $3.9 million. This amount is reflected in additional paid in capital. The Company recorded a gain from the extinguishment of the debt in the amount of $2.0 million which is reflected in other income (expense), net in the consolidated statement of operations in the year ended December 31, 2014. In addition, as the warrants could be exercised for Series B convertible preferred stock any time after achieving a QLT, which was met on December 9, 2013 and before the Series C convertible preferred stock financing, in April and May 2014, all holders of these warrants elected to fully exercise warrants for 4,279,620 shares of Series B convertible preferred stock. During the years ended December 31, 2014 and 2013, the Company recognized total interest expense of $3.9 million and 4.8 million, respectively, related to the accrued interest and amortization of the debt discount.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Purchase Commitments The Company enters into contracts in the normal course of business with contract research organizations for preclinical studies and clinical trials and contract manufacturing organizations (“CMOs”) for the manufacture of drug materials. As of December 31, 2015, the Company had a commitment of $14.5 million with CMOs for the manufacture of clinical trial material due within a year. The Company has an agreement with Medpace, Inc. (“Medpace”), a related party (see Note 15) and, a CRO, which provides for a minimum fee commitment of $35.0 million in the aggregate for clinical trial services; however, the agreement is cancelable without cause by either party upon 30 days prior notification. As of December 31, 2015, the Company has fulfilled the minimum fee commitment related to this agreement. Facility Leases The Company leases office spaces for its corporate headquarters in Redwood City, California and for laboratory facilities in Camarillo, California under operating lease agreements. On July 6, 2015, the Company entered into a new office lease (the “New Lease”) with Hudson 333 Twin Dolphin Plaza, LLC (the “Landlord”) to lease approximately 27,532 square feet of office space located in Redwood City, California (the “Premises”) for the Company’s new corporate headquarters. The Company leased office space located in Redwood City, California, pursuant to a lease dated September 26, 2011 (as amended, the “Current Lease”), which expired pursuant to the terms described below under “Amendment to Current Lease.” The New Lease commenced on December 1, 2015 and the Company moved into the new facility in December 2015. The Company entered into the Seventh Amendment to the Current Lease (the “Seventh Amendment”) with its current landlord when the New Lease was entered into. The Seventh Amendment provided early termination of the Current Lease which was effective in December 2015 when the New Leased commenced. The New Lease provides for annual base rent of approximately $1.6 million in the first year of the Lease Term, which increases on an annual basis up to approximately $1.9 million for the final year of the Lease Term. The New Lease also provides for certain limited rent abatements in the second year of the Lease Term. The Company will be entitled to a one-time improvement allowance of approximately $1.2 million for costs related to the design and construction of Company improvements that are permanently affixed to the Premises. See the future minimum lease payment schedule for all facility leases below. In addition, the Company obtained a standby letter of credit (the “Letter of Credit”) in an amount of approximately $0.8 million, which may be drawn down by the Landlord to be applied for certain purposes upon the Company’s breach of any provisions under the New Lease. Provided that no default occurs under the terms of the New Lease, the Company will be entitled to periodically reduce the amount of the Letter of Credit down to approximately $0.3 million as of the last day of the sixtieth full calendar month of the Lease Term. The Company has recorded the $0.8 million Letter of Credit in restricted cash, non-current within its consolidated balance sheet at December 31, 2015. Rent expense is recognized on a straight-line basis over the term of the leases and accordingly, the Company records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. The corporate headquarters new lease expires in November 2022, and the Camarillo laboratory lease expires in June 2017 with an option to extend for three years. The future minimum lease payments for these facilities as of December 31, 2015 are as follows (in thousands): Year ending December 31, 2016 $ 1,692 2017 1,276 2018 1,669 2019 1,719 2020 and thereafter 5,315 Total minimum lease payments $ 11,671 Rent expense was $1.8 million, $0.8 million and $0.4 million for the years ended December 31, 2015, 2014 and 2013, respectively. Guarantees and Indemnifications In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company would assess the likelihood of any adverse judgments or related claims, as well as ranges of probable losses. In the cases where the Company believes that a reasonably possible or probable loss exists, it will disclose the facts and circumstances of the claims, including an estimate range, if possible. As of December 31, 2015, the Company is subject to one claim that is probable or reasonably possible and consequently has recorded a related liability of $50,000.

Convertible Preferred Stock War

Convertible Preferred Stock Warrants	12 Months Ended
	Dec. 31, 2015
Temporary Equity Disclosure [Abstract]
Convertible Preferred Stock Warrants	9. Convertible Preferred Stock Warrants 2011 Warrants A In January 2011, in conjunction with the issuance of the 2011 convertible note agreements, the Company issued warrants to purchase shares of its newly authorized shares of preferred stock upon a financing event (“2011 Warrants A”). In March 2011, as a result of the Series A convertible preferred stock financing event, the 2011 Warrants A became exercisable warrants to purchase 63,923 shares of Series A convertible preferred stock with an exercise price of $1.2503 per share. Immediately prior to the closing of the Company’s IPO in November 2014, all of the outstanding warrants were exercised, for cash or on a net cash basis for 62,251 shares of Series A convertible preferred stock resulting in cash proceeds of $55,000. 2011 Warrants B From July to December 2011, the Company issued the 2011 Warrants B with an exercise price of $0.0167 per share in conjunction with the issuance of the 2011 convertible not agreements. In January 2012, as a result of the Series B convertible preferred stock financing event, the 2011 Warrants B became exercisable warrants to purchase 352,448 shares of Series B convertible preferred stock. In June 2012, warrants to purchase 57,347 of Series B preferred stock were exercised, resulting in cash proceeds of approximately $1,000. During April and May 2014, warrants to purchase 172,042 shares of Series B convertible preferred stock were cash exercised for $3,000 and the remaining outstanding warrants were exercised, for cash or on a net basis resulting in the issuance of 123,051 shares of Series B convertible preferred stock for $2,000 immediately prior to the closing of the Company’s IPO in November 2014. 2013 Warrants From July to September 2013, the Company issued the 2013 Warrants with the exercise price of $0.0167 per share in conjunction with the issuance of the Bridge Loans (see Note 7). The estimated fair value of the 2013 Warrants at issuance was $13.6 million based on probability-weighted values of the warrants under the qualifying event scenarios. The Company recognized the fair value of the 2013 Warrants up to the total aggregate Bridge Loans of $10.0 million as the debt cannot be reduced to less than zero. The remaining $3.6 million of the total fair value of the 2013 Warrants was recognized immediately within other income (expense), net, in the consolidated statement of operations. In December 2013, following the receipt of the upfront license payment from the Baxalta license agreement (see Note 5), the Company met the QLT criteria. As a result, the 2013 Warrants became exercisable to purchase 4,279,620 shares of Series B convertible preferred stock. During April and May 2014, warrants to purchase 4,279,620 shares of Series B convertible preferred stock were exercised for $71,000. The 2011 Warrants A, 2011 Warrants B and 2013 Warrants were classified as convertible preferred stock warrant liabilities and subject to remeasurement at each balance sheet date. The fair value of the convertible preferred stock warrants was determined based on Level 3 inputs. The Company determined the fair value of the warrants by allocating the Company’s equity value using a combination of the Probability-Weighted Expected Return Method (“PWERM”) and the Option-Pricing Method (“OPM”). The Company’s equity value was allocated among preferred stock, common stock, warrants and stock options expected to be outstanding at the expected future liquidity events based on the rights and preferences of each class. The OPM considers a distribution of future equity values based on the time to liquidity and the expected volatility in the total equity value. Inputs to the OPM include assumptions related to the fair value of the shares, the exercise price, expected volatility, expected term, risk-free interest rate, and the expected dividend yield. The estimated expected volatility was based on the volatility of common stock of a group of comparable, publicly-traded companies. The estimated expected term was based on the estimated time to liquidity event. The risk-free interest rate was based on the U.S. Treasury yield for a term consistent with the estimated expected term. The significant unobservable input used in the fair value measurement of the convertible preferred stock warrant liability is the fair value of the underlying preferred stock at the valuation remeasurement date. The PWERM considers specific future equity values based on knowledge of a potential transaction or IPO. The range of future equity values is probability-weighted and discounted at a risk-adjusted rate. Some of the valuations applied a combination of the two allocation methods to capture the fair value of the warrants. During 2014, the warrants were valued using the PWERM exclusively based on the expectation for an IPO in November 2014. The size of the IPO and the implied pre-money total equity values were used to support the warrants value. Generally, increases (decreases) in the fair value of the underlying preferred stock would result in a directionally similar impact to the fair value measurement. The change in the fair value of the convertible preferred stock warrant liability was recognized in other expense, net within the consolidated statements of operations. The net change in the fair value of the warrant liability was an increase of $15.9 million and an increase of $8.9 million for the years ended December 31, 2014 and 2013, respectively. The Company adjusted the liability for changes in fair value at the time of the exercise and then reclassified the liability to the respective series of preferred stock. Any remaining warrants outstanding immediately prior to the Company’s IPO in November 2014 were exercised, for cash or on a net basis, and the fair value of the warrants were recorded to the respective series of convertible preferred. As the result of all of the outstanding warrant exercises during 2014, the Company reclassified $1.0 million and $39.3 million to Series A and Series B preferred stock, respectively, reducing the preferred stock warrant liability to zero by December 31, 2014. The following table sets forth a summary of the changes in the estimated fair value of the convertible preferred stock warrants for the year ended December 31, 2014 (in thousands): December 31, 2014 Balance, beginning of year $ 24,251 Warrants issued in connection with notes payable — Initial fair value of the warrants issued in excess of debt proceeds recognized in other income (expense), net — Warrants exercised (40,150 ) Change in fair value of convertible preferred stock warrant liability 15,899 Balance, end of year $ —

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Dec. 31, 2015
Warrants And Rights Note Disclosure [Abstract]
Common Stock Warrants	10. Common Stock Warrants In March 2014, the Company issued warrants to purchase 553,274 shares of common stock with the exercise price of $1.667 per share to two employees and one consultant for past services. The warrants were vested and exercisable upon issuance and would have expired at the earlier of: (i) March 28, 2024, (ii) an IPO or (iii) the consummation of a liquidation event. If the holders had not exercised these warrants prior to the closing of a liquidation event or the IPO, these warrants would have automatically been net exercised. The Company valued the warrants at $2.7 million using the Black-Scholes option-pricing model with the following assumptions on the date of grant: exercise price of $1.667 per share, fair value of the common stock of $5.73 per share, expected volatility of 93% and 96% for the employee and consultant warrants, respectively, risk-free interest rate of 1.74% and 2.73% for the employee and consultant warrants, respectively, expected terms of 5 and 10 years for the employee and consultant warrants, respectively, and dividend yield of zero. The grant date fair value per warrant share was $4.95 for employees and $5.42 for the consultant, resulting in warrant valuations of $2.6 million and $144,000 for the employees and consultant, respectively. Due to the immediate vesting and exercisability of the warrants upon issuance, the Company immediately recognized $1.3 million and $1.4 million of stock-based compensation in research and development expense and general and administrative expense, respectively, in the consolidated statement of operations. In November 2014, all of the warrants outstanding to purchase common stock were net exercised, which resulted in the issuance of 491,580 shares of common stock upon the closing of the IPO.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2015
Equity Method Investment Summarized Financial Information Liabilities And Equity [Abstract]
Stockholders' Equity (Deficit)	11. Stockholders’ Equity (Deficit) Common Stock In October 2014, the Company’s board of directors and stockholders approved the amendment and restatement of the Company’s certificate of incorporation to be effective immediately prior to the consummation of the IPO. The Amended and Restated Certificate of Incorporation was filed on November 12, 2014, which provides for 300,000,000 authorized shares of common stock with a par value of $0.0001 per share and 5,000,000 authorized shares of preferred stock with a par value of $0.0001 per share. Initial Public Offering On November 6, 2014, the Company’s registration statement on Form S-1 (File No. 333-198936) relating to the IPO of its common stock was declared effective by the Securities and Exchange Commission (“SEC”) and the shares began trading on The NASDAQ Global Market on November 6, 2014. The price of the shares sold in the IPO was $13.50 per share. The IPO closed on November 12, 2014, pursuant to which the Company sold 6,803,702 shares of common stock, including the sale of 507,402 shares of common stock to the underwriters upon their partial exercise of their over-allotment option. The Company received total gross proceeds from the offering of $91.8 million, after deducting underwriting discounts and commissions of $6.4 million and offering expenses of $5.2 million, the net proceeds were $80.2 million. In connection with the closing of the IPO, all shares of convertible preferred stock then outstanding converted into 21,316,519 shares of common stock, including 185,302 outstanding convertible preferred stock warrants were exercised, for cash or on a net basis. Also, all outstanding warrants for common stock were exercised, on a net basis, into 491,580 shares of common stock in connection with the IPO. Follow-on Offering In March 2015, the Company’s registration statement on Form S-1 (File No. 333-202936) relating to its follow-on offering of its common stock was declared effective by the SEC. The price of the shares sold in the follow-on offering was $29.00 per share. The follow-on offering closed on April 7, 2015, pursuant to which the Company sold 4,137,931 shares of common stock. The Company received total gross proceeds from the offering of $120.0 million. After deducting underwriting discounts and commissions of $7.2 million and offering expenses of $0.6 million, the net proceeds were $112.2 million. Private Placement with Baxalta On September 10, 2015, the Company completed a private placement and entered into a Purchase Agreement with Baxalta. Pursuant to the Purchase Agreement, the Company sold Baxalta an aggregate of 390,167 shares of common stock for aggregate gross proceeds of approximately $10 million. The purchase price for each share was $25.63, which was equal to the closing trading price of the Company's common stock on the NASDAQ Global Market on the day of pricing, September 9, 2015. The securities sold and issued in connection with the private placement are not registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Baxalta GmbH. Pursuant to the Registration Rights Agreement, the Company filed a registration statement on Form S-3 (File No. 333-208625) with the SEC on December 18, 2015 for purposes of registering the resale of the shares. The Registration Statement on Form S-3 was declared effective by the SEC on January 21, 2016. Convertible Preferred Stock In May 2014, the Company completed a financing resulting in the issuance of 5,488,892 shares of Series C convertible preferred stock, for net cash proceeds of $54.7 million. In conjunction with the Series C convertible preferred stock financing, the Bridge Loans and the related accrued interest were automatically converted into 1,058,089 shares of Series C convertible preferred stock at the price per share of such financing, and the collateralized security interest of the Company’s assets, tangible and intangible, under the Bridge Loans was released. In addition, the Company issued 9,997 shares of Series C convertible preferred stock in exchange for consulting services. The Company recorded the convertible preferred stock at fair value on the dates of issuance. The Company classified the convertible preferred stock outside of stockholders’ deficit because the shares contained liquidation features that were not solely within the Company’s control. During April and May 2014, warrants to purchase 4,451,662 shares of Series B convertible preferred stock were exercised into Series B convertible preferred stock for $74,000, which included the 4,279,620 shares of Series B convertible preferred stock warrants related to the Bridge Loan (see Note 9). ). In November 2014, in connection with the closing of the IPO, warrants to purchase 62,251 shares and 123,051 shares of Series A and B convertible preferred stock, respectively, were exercised on a cash or net basis for $57,000. In connection with the closing of the IPO in November 2014, all outstanding shares of Series A, Series B and Series C convertible preferred stock shares were converted into 21,316,519 shares of common stock on a one-for-one basis. As such, no convertible preferred stock shares were outstanding as of December 31, 2014.

Stock Option Plans and Stock-Ba

Stock Option Plans and Stock-Based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Option Plans and Stock-Based Compensation	12. Stock Option Plans and Stock-Based Compensation Restricted Common Stock (“Founders Shares”) In October 2010 and January 2011, the Company issued 4,130,173 shares and 968,804 shares of common stock, respectively, with a purchase price of $0.0083 per share to its founders under the Founder Shares agreements. Under the Founders Shares agreements, the Company has the right to repurchase the common stock which right lapses monthly in equal installments over four years. In order to vest, the holders are required to provide continued service to the Company. Upon vesting, the appropriate amounts are transferred from liabilities to additional paid in capital. If the holder of any unvested restricted common stock is terminated for any reason, the Company has the right to repurchase the unvested shares at the stockholder’s original purchase price. As such, the shares subject to future vesting were not deemed outstanding for accounting purposes until the shares vested. In July 2012 and March 2014, the Company repurchased 286,817 and 239,952 shares of founders’ common stock from founders at $0.0083 per share, respectively. A summary of the Company’s non-vested restricted stock for the periods is as follows: Number of Shares Non-vested as of December 31, 2014 21,245 Vested (21,245 ) Non-vested as of December 31, 2015 — The Company recognized stock-based compensation over the vesting term of four years based on the fair value of the common stock on the dates of issuance. The restricted common stock granted to an employee is valued using the Black-Scholes options pricing model based on the common stock fair value at the time of the grant. For restricted common stock issued to consultants, the Company remeasured the fair value of the restricted shares as they vest at each reporting period using the Black-Scholes option-pricing model reflecting the remaining vesting period. The stock-based compensation expense recorded related to the founder’s shares was as follows (in thousands): Year Ended December 31, 2015 2014 2013 Research and development $ 9 $ 1,547 $ 227 General and administrative — 4 1,054 $ 9 $ 1,551 $ 1,281 2010 Stock Plan In 2010, the Company adopted the 2010 Stock Plan (the “2010 Plan”) and granted options under this plan until November 2014 which is when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding under the 2010 Plan. The 2010 Plan provided for the Company to grant shares and/or options to purchase shares of common stock to employees, directors, consultants, and other service providers at prices not less than the fair value at the date of grant for incentive stock options and nonstatutory options. These options were granted to generally vest over four years, expire ten years from the date of grant, and are generally exercisable after vesting. Unvested options exercised are subject to the Company’s repurchase right that lapses as the options vest. As of December 31, 2015 and 2014, no shares were subject to repurchase under the 2010 Plan. In November 2014, the board of directors adopted the Company’s 2014 Equity Incentive Award Plan (the “2014 Plan”) and any remaining unissued shares available under the 2010 Plan were transferred into the 2014 Plan. As such, no more options may be issued under the 2010 Plan. As of December 31, 2015, a total of 4,560,904 shares of common stock are subject to options outstanding under the 2010 plan, which shares will become available under the 2014 Plan to the extent the options are forfeited or lapse unexercised. 2014 Equity Incentive Award Plan In October 2014, the Company’s board of directors and its stockholders approved the establishment of the 2014 Equity Incentive Plan (the “2014 Plan”), effective upon the date upon which the registration statement for the IPO was declared effective, which was November 6, 2014. As of the date of the IPO, the Company reserved for issuance under the 2014 Plan a total of 2,300,000 shares of its common stock, plus any additional shares that would otherwise return to the 2010 Plan as a result of forfeiture, termination or expiration of awards previously granted under the 2010 Plan. In addition, the 2014 Plan provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with 2015, equal to four percent (4%) of the number of shares of the Company’s common stock outstanding as of such date or a lesser number of shares as determined by the Company’s board of directors. Employee Stock Purchase Plan In October 2014, the Company’s board of directors and its stockholders approved the establishment of the 2014 Employee Stock Purchase Plan (“ESPP”). The Company will reserve for issuance 320,000 shares of its common stock and provide for annual increases in the number of shares available for issuance on the first business day of each fiscal year, beginning with the Company’s fiscal year following the year of this offering, equal to the lesser of one percent (1%) of the number of shares of the Company’s common stock outstanding as of such date, 320,000 shares of common stock, or a number of shares as determined by the Company’s board of directors. The following table sets forth the summary of option activities under the 2014 and 2010 Plans: Options Outstanding Shares Available for Grant Number of Options Weighted-Average Exercise Balances at December 31, 2014 2,652,500 5,770,307 $ 2.909 Authorized 1,330,319 — — Granted - at fair value (3,217,313 ) 3,217,313 28.020 Exercised — (861,137 ) 1.660 Forfeited 317,641 (317,641 ) 15.066 Balances at December 31, 2015 1,083,147 7,808,842 $ 12.898 Additional information related to the status of options as of December 31, 2015 is summarized as follows: Number of Options Weighted- Average Exercise Price Weighted- Average Contractual Terms (Years) Aggregate Intrinsic Value (in thousands) Options outstanding 7,808,842 $ 12.898 8.27 $ 94,220 Options vested and expected to vest 7,747,817 $ 12.839 8.26 $ 93,860 Options vested and exercisable 3,054,854 $ 4.956 7.34 $ 56,696 Valuation of Awards Granted to Employees The Company estimated the fair value of each stock award on the date of grant using the Black-Scholes option-pricing model. The weighted average assumptions used to value options granted to employees under the Plan during the years ended December 31, 2015, 2014 and 2013 were as follows: Year Ended December 31, 2015 2014 2013 Expected term (years) 6.00 6.50 5.51 Expected volatility 78 % 99 % 108 % Risk-free interest rate 1.62 % 2.05 % 1.23 % Expected dividend yield 0 % 0 % 0 % Expected Term The expected term represents the period for which the stock-based awards are expected to be outstanding and is based on the options’ vesting term, contractual term and industry peers. The Company did not have sufficient historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior. Expected Volatility The Company used an average historical stock price volatility of industry peers as representative of future stock price volatility since the Company does not have any trading history for its common stock. Risk-Free Interest Rate The Company based the risk-free interest rate by using an equivalent to the expected term based on the U.S. Treasury constant maturity rate as of the date of grant. Expected Dividends The Company has not paid and does not anticipate paying any dividends in the near future, and therefore used an expected dividend yield of zero in the valuation model. The stock-based compensation expense recorded related to options granted to employees was as follows (in thousands): Year Ended December 31, 2015 2014 2013 Research and development $ 6,460 $ 1,580 $ 431 General and administrative 8,289 3,934 309 $ 14,749 $ 5,514 $ 740 During the years ended December 31, 2015, 2014 and 2013, the total estimated fair value of the options vested was $14.6 million, $4.2 million and $0.7 million, respectively and the estimated weighted-average grant-date fair value of options granted was $18.42, $6.65 and $1.88 per share, respectively. The aggregate intrinsic value of options exercised during the years ended December 31, 2015, 2014 and 2013 was $1.4 million, $0.4 million and $0, respectively. As of December 31, 2015, total unrecognized stock-based compensation expenses related to unvested employee stock options was $55.2 million, which is expected to be recognized on a straight-line basis over a weighted-average period of approximately 3.15 years. In November 2014, the Company entered into a separation agreement with its former CFO and granted accelerated vesting of options and extended the exercise period for those vested options. In connection with the option modification, the Company recognized stock-based compensation expense of $1.2 million to general and administrative expense in its consolidated statements of operations for the year ended December 31, 2014, which is included in the $3.9 million in the above stock-based compensation table. Nonemployees Stock-Based Compensation The Company granted 198,750, 113,913 and 74,983 stock options to purchase shares of common stock to nonemployees during the years ended December 31, 2015, 2014 and 2013. The weighted-average exercise price of the options granted in 2015, 2014 and 2013 was $ 26.51, $4.42 and $1.42 per share, respectively. For the years ended December 31, 2015, 2014 and 2013, the Company recorded stock-based compensation expense related to options granted to nonemployees of $2.0 million, $1.3 million and $24,000, respectively. The Company remeasures the fair value of the unvested nonemployee options at each period using the Black-Scholes option-pricing model reflecting the same assumptions as applied to employee options in each of the reported years, other than the expected life, which is assumed to be the remaining contractual life of the options.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes The Company utilizes the liability method of accounting for deferred income taxes. Under this method, deferred tax liabilities and assets are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets because, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. A reconciliation of the statutory U.S. federal rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2015 2014 2013 Percent of pre-tax income: U.S. federal statutory income tax rate 34.00 % 34.00 % 34.00 % State taxes, net of federal benefit 0.70 (1.65 ) 3.97 Permanent items (1.25 ) (10.80 ) (12.40 ) Research and development credit 2.46 3.11 4.53 Net operating loss (0.01 ) 0.01 — InteKrin purchase price allocation — 0.73 — Other 0.09 0.02 — Change in valuation allowance (35.99 ) (25.42 ) (30.10 ) Effective income tax rate — % — % — % Significant components of the Company’s net deferred tax assets as of December 31, 2015 and 2014 consist of the following (in thousands): December 31, 2015 2014 Net operating loss carryforwards $ 91,334 $ 34,463 Research and development credits 12,980 6,032 Depreciation and amortization 778 854 Stock-based compensation 5,111 1,428 Other accruals 2,236 940 Deferred revenue 23,237 12,762 Gross deferred tax assets 135,676 56,479 In-process research and development (891 ) (892 ) Gross deferred tax liabilities (891 ) (892 ) Total net deferred tax asset 134,785 55,587 Less valuation allowance (134,785 ) (55,587 ) Net deferred tax assets $ — $ — The valuation allowance increased $79.2 million, $22.1 million and $16.1 million during the years ended December 31, 2015, 2014 and 2013, respectively. As of December 31, 2015, the Company had federal net operating loss carryforwards of approximately $281.6 million, which will start to expire beginning in 2031, and various state net operating loss carryforwards of approximately $94.8 million, which have various expiration dates beginning in 2031. Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization. As of December 31, 2015, the Company had federal research and development credit carryforwards of approximately $15.1 million, which will start to expire in 2031, and state research and development credit carryforwards of approximately $5.2 million, which can be carried forward indefinitely. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. Due to the Company’s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its deferred tax assets will not be realized, and therefore, the deferred tax assets are fully offset by a valuation allowance at December 31, 2015 and 2014. At December 31, 2015, the portion of the federal net operating loss carryforwards related to stock option deductions is approximately $21.7 million, which is not included in the Company’s gross or net deferred tax assets. Pursuant to ASC 718-740-25-10, the tax effect of the stock option benefit of approximately $7.4 million will be recorded to equity when they reduce cash taxes payable in the future. The Company files U.S, California, and other state income tax returns with varying statutes of limitations. The tax years from 2011 forward remain open to examination due to the carryover of unused net operating losses and tax credits. A reconciliation of the Company’s unrecognized tax benefits for the years ended December 31, 2015 and 2014 is as follows (in thousands): Year Ended December 31, 2015 2014 2013 Balance at beginning of year $ 3,816 $ 749 $ 73 Additions based on tax positions related to current year 3,633 861 319 Additions for tax positions of prior years 3,156 2,206 357 Balance at end of year $ 10,605 $ 3,816 $ 749 As of December 31, 2015 and 2014, the Company had approximately $10.6 million and $3.8 million, respectively, of unrecognized benefits, none of which would currently affect the Company’s effective tax rate if recognized due to the Company’s deferred tax assets being fully offset by a valuation allowance. The Company does not believe there will be any material changes in its unrecognized tax positions over the next twelve months. During the years ended December 31, 2015, 2014 and 2013, the Company did not recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease during the next 12 months.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Coherus	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Coherus	14. Net Loss Per Share Attributable to Coherus The following table sets forth the computation of the basic and diluted net loss per share attributable to Coherus (in thousands, except share and per share data): Years Ended December 31, 2015 2014 2013 Numerator: Net loss attributable to Coherus $ (223,260 ) $ (87,133 ) $ (53,635 ) Denominator: Weighted-average common shares outstanding 37,125,617 8,520,100 4,828,214 Less: weighted-average unvested common shares subject to repurchase (1) (3,609 ) (333,571 ) (1,496,194 ) Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted 37,122,008 8,186,529 3,332,020 Net loss per share attributable to Coherus, basic and diluted $ (6.01 ) $ (10.64 ) $ (16.10 ) (1) Shares were excluded as such shares represent restricted common stock (founders’ shares) which is vesting contingently upon the holders’ continued services to the Company. The following outstanding dilutive potential shares have been excluded from the calculation of diluted net loss per share attributable to Coherus due to their anti-dilutive effect: Outstanding as of December 31, 2015 2014 2013 Stock options outstanding 7,808,842 5,770,307 3,047,396 Convertible preferred stock — — 9,153,906 Convertible preferred stock warrants — — 4,638,644 Total 7,808,842 5,770,307 16,839,946 In addition, 358,384 shares of common stock contingently issuable upon the successful achievement of an objective associated with contingent consideration payable to former InteKrin stockholders have been excluded from the calculation of diluted net loss per share attributable to Coherus for the year ended December 31, 2014. On March 6, 2015, the contingent issuable shares were settled (see Note 3).

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	15. Related Party Transactions Notes Receivable from Founders In December 2011, the Company entered into unsecured promissory notes (“Notes Receivable”) agreement with the four founders of the Company. Of the four founders, three are members of the executive team of the Company. The aggregate amount of Notes Receivable was $133,000 at the issuance date and the Notes Receivable bore interest at 0.2% per annum. In May 2014, the Company forgave the outstanding balance of Notes Receivable of $111,000 and the related accrued interest of approximately $1,000, which is reflected in the Company’s consolidated statement of operations for the year ended December 31, 2014, as interest expense. Daiichi Sankyo In January 2012, Company entered into a license agreement with Daiichi Sankyo (see Note 5), under which the Company issued 2,867,426 shares of Series B convertible preferred stock. As such, Daiichi Sankyo was deemed to be a related party by ownership of more than 10% of the Company’s equity. Upon the consummation of the Company’s IPO, Daiichi Sankyo’s ownership percentage decreased to less than 10% of the Company’s equity; therefore, as of November 2014, Daiichi Sankyo was no longer considered a related party. As a result, the consolidated balance sheets as of December 31, 2015 and 2014 no longer reflects these balances as related party amounts, and the consolidated statement of operations for the year ended December 31, 2015 does not reflect any transactions with Daiichi Sankyo as related party. For the years ended December 31, 2014 and 2013, the Company recognized related party transactions of $1.9 million and $2.0 million as collaboration and license revenue–related party in the Company’s consolidated statements of operations, respectively. In addition, the Company recognized $7.1 million and $1.3 million as a reduction of research and development expense related to the costs reimbursed by Daiichi Sankyo in the Company’s consolidated statements of operations for the years ended December 31, 2014 and 2013, respectively. Transactions Associated with Cook In January and December 2012, the Company issued a total of 2,150,569 shares of Series B convertible preferred stock to Cook as consideration for past and future services. As such, Cook was deemed to be a related party by ownership of more than 10% of the Company’s equity. During the second quarter of 2014, Cook divested a majority of its shares of the Company’s Series B convertible preferred stock; therefore, as of December 31, 2014, Cook was no longer considered a related party. As a result, the consolidated balance sheets as of December 31, 2015 and 2014 no longer reflects these balances as related party amounts, and the consolidated statement of operations for the year ended December 31, 2015 no longer reflect transactions with Cook as related party transactions. For the years ended December 31, 2014 and 2013, the Company recognized $4.5 million and $6.1 million, respectively, of services rendered by Cook within research and development in the consolidated statements of operations. Transactions Associated with Medpace Agreement One member of the Company’s board of directors is also the chief executive officer of Medpace. As such, Medpace was deemed to be a related party. As of December 31, 2015, the Company had $10.9 million in prepaid assets (prepaid clinical, material, manufacturing and other–related parties), $3.5 million in accounts payable–related parties, and $6.1 million in accrued and other liabilities (accrued clinical, manufacturing and other–related parties), all reflected on the Company’s consolidated balance sheet associated with Medpace. As of December 31, 2014, the Company had $6.0 million in prepaid assets (prepaid clinical, material, manufacturing and other–related parties), $1.9 million in accounts payable–related parties, and $3.0 million in accrued and other liabilities (accrued clinical, manufacturing and other–related parties), all reflected on the Company’s consolidated balance sheet associated with Medpace. The Company recognized $42.5 million, $24.1 million and $4.7 million during years ended December 31, 2015, 2014 and 2013, respectively, for services rendered by Medpace within research and development expense in the consolidated statements of operations. Additionally, the Company recognized $0.5 million of interest expense for the year ended December 31, 2013 associated with extended payment arrangement with Medpace. The Company also has an agreement with Medpace which provides for a minimum fee commitment of $35.0 million for clinical trial services which is further discussed in Note 8. As of December 31, 2015, the Company has fulfilled the minimum fee commitment related to this agreement. Recruiting Services One member of the Company’s board of directors is the chief executive officer of a company that provides recruiting services to the Company. As such, the recruiting services provided were deemed to be related party transactions. As of December 31, 2014, the Company had $90,000 in accounts payable-related parties reflected on the Company’s consolidated balance sheet. As of December 31, 2015, there were no such balances in the Company’s consolidated balance sheet. The Company recorded in research and development expense in its consolidated statements of operations, $258,000, $241,000 and $35,000 for the years ended December 31, 2015, 2014 and 2013, respectively, for services rendered by the recruiting company. The Company recorded in general and administrative expense in its consolidated statements of operations, $559,000, $597,000 and $18,000 for the year ended December 31, 2015, 2014 and 2013, respectively, for services rendered by the recruiting company. Convertible Notes — Related Parties In the third quarter of 2013, the Company entered into Bridge Loans with certain investors, including existing stockholders, some members of the Company’s board of directors and their affiliated companies and some members of management, for a total aggregate amount of $10.0 million and issued the 2013 Warrants to purchase shares of the Company’s preferred stock at an exercise price of $0.0167 per share (see Note 9). In May 2014, the Company completed a preferred stock financing and contemporaneously the Bridge Loans and the related accrued interest were automatically converted into Series C preferred stock (see Note 7). For the years ended December 31, 2014 and 2013, the Company recognized $2.7 million and $3.3 million, respectively, of interest expense related to the debt and the amortization of the debt discount in the Company’s consolidated statements of operations. InteKrin Acquisition In February 2014, the Company completed the acquisition of the InteKrin for total consideration of $5.0 million (see Note 6). Mr. Dennis M. Lanfear, the chief executive officer of the Company, was the chairman of the board and acting president of InteKrin at the time of the acquisition. As such, the InteKrin acquisition was a related party transaction. Mr. Lanfear also owns 10% of the outstanding securities of InteKrin Russia, a majority owned subsidiary of InteKrin. Other Assets – Related Party In December 2014, the Company entered into an agreement with an officer of the Company, in which the officer irrevocably transferred his rights to a certain number of shares with an aggregate value of $1.7 million. This amount is reflected in the Company’s consolidated balance sheet at December 31, 2014 as “other assets-related party”. This transaction was settled in July 2015.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events In February 2016, the Company issued and sold $100.0 million aggregate principal amount of its 8.2% senior convertible notes due 2022 (“the Notes”). These Notes require quarterly interest distributions at a fixed coupon rate of 8.2% until maturity, redemption or conversion, which will be no later than March 31, 2022. The Notes are convertible into shares of common stock at an initial conversion rate of 44.7387 shares of common stock per $1,000 principal amount of the Notes (equivalent to a conversion price of approximately $22.35 per share of common stock, representing a 60% premium over the average last reported sale price of the Company’s common stock over the 15 trading days preceding the date the notes were issued), subject to adjustment in certain events. After March 31, 2020, the full amounts of the Notes not previously converted are redeemable for cash at the Company’s option if the last reported sale price per share of the Company’s common stock exceeds 160% of the conversion price on 20 or more trading days during the 30 consecutive trading days preceding the date on which the Company sends notice of such redemption to the holders of the Notes. Upon conversion of the Notes by a holder, the holder will receive shares of the Company’s common stock, together, if applicable, with cash in lieu of any fractional share. At maturity or redemption, if not earlier converted, the Company will pay 109% of the par value of the Notes, together with accrued and unpaid interest, in cash. The holders of the Notes are Healthcare Royalty Partners III, L.P., which holds $75.0 million in aggregate principal amount, and three related party investors, KKR Biosimilar L.P., which holds $20.0 million, MX II Associates LLC, which holds $4.0 million, and KMG Capital Partners, LLC, which holds $1.0 million.

Supplementary Data - Quarterly

Supplementary Data - Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information	17. Supplementary Data – Quarterly Financial Data (Unaudited) The following table presents certain unaudited consolidated quarterly financial information for each of the quarters ended December 31, 2015 and 2014: 2015 Quarter End (in thousands, except per share data) March 31 June 30 September 30 December 31 Total revenue $ 5,810 $ 6,866 $ 7,167 $ 10,198 Total operating expenses 42,558 65,761 78,384 62,405 Net loss (40,839 ) (59,034 ) (71,485 ) (52,580 ) Net loss attributable to Coherus (40,725 ) (58,810 ) (71,334 ) (52,391 ) Net loss per share attributable to Coherus, basic and diluted (1.22 ) (1.56 ) (1.86 ) (1.35 ) 2014 Quarter End March 31 June 30 September 30 December 31 Total revenue $ 3,596 $ 4,965 $ 16,052 $ 6,493 Total operating expenses 17,357 22,903 22,475 33,053 Net loss (25,170 ) (25,070 ) (7,914 ) (29,023 ) Net loss attributable to Coherus (25,170 ) (24,957 ) (7,872 ) (29,134 ) Net loss per share attributable to Coherus, basic and diluted (6.04 ) (5.96 ) (1.79 ) (1.47 )

Basis of Presentation and Sum27

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The accompanying consolidated financial statements include the accounts of Coherus and its wholly owned subsidiaries as of December 31, 2015: Coherus Intermediate Corp, Coherus Oncology, Inc., InteKrin Therapeutics Inc. (“InteKrin”), and InteKrin’s 82.5% majority owned subsidiary of InteKrin Russia. Unless otherwise specified, references to the Company are references to Coherus and its consolidated subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.
Reclassification	Reclassification To maintain comparability among the periods presented, the Company reclassified certain prior period amounts to a separate line item that was not included in the prior period presentation. Within Note 4, Accrued Liabilities, in the Notes to the Consolidated Financial Statements for the year ended December 31, 2014, the Company reclassified amounts that were recorded within accrued other to accrued clinical and manufacturing. The reclassification had no impact on the total current accrued liabilities for the periods presented.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, valuation of deferred tax assets, impairment of goodwill and long-lived assets, the valuation of acquired intangible assets, clinical trial accruals, revenue recognition period, as well as certain accrued liabilities; and in prior years, common stock valuation, the valuations of the convertible preferred stock warrant liability and embedded derivative instruments. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.
Foreign Currency	Foreign Currency The functional currency of InteKrin Russia, which the Company acquired in February 2014, is the Russian Ruble. Accordingly, the financial statements of this subsidiary are translated into U.S. dollars using appropriate exchange rates. Unrealized gains or losses on translation are recognized in accumulated other comprehensive loss in the consolidated balance sheet. For the years ended December 31, 2015, 2014 and 2013, the foreign exchange gains and losses recorded in other expense, net in the consolidated statements of operations were a net loss of $386,000, a net gain of $671,000 and a net loss of $34,000, respectively.
Segment Reporting and Customer Concentration	Segment Reporting and Customer Concentration The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing biosimilar products, and, as part of the InteKrin acquisition, small molecules (see Note 6). The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Long-lived assets are primarily maintained in the United States of America. The following table summarizes revenue by geographic region (in thousands): Year Ended December 31, 2015 2014 2013 United States $ 27,802 $ 28,481 $ 726 Rest of world 2,239 2,625 2,025 Total revenue $ 30,041 $ 31,106 $ 2,751 Customer Concentration Customers whose collaboration and license revenue accounted for 10% or more of total revenues were as follows: Year Ended December 31, 2015 2014 2013 Daiichi Sankyo - related party (1) * * 74 % Baxalta 93 % 92 % 26 % * less than 10% (1) Represents revenue from Daiichi Sankyo through November 12, 2014 as a related party, a holder of more than 10% of our common stock until the closing of our IPO.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs, which primarily consist of direct incremental legal and accounting fee, are capitalized in other assets until the completion of the offering. These deferred offering costs will be reclassified to additional paid-in capital upon the closing of the offering. There was $137,000 in deferred offering costs capitalized as of December 31, 2015 and none capitalized as of December 31, 2014.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents.
Restricted Cash	Restricted Cash Restricted cash consists of cash held in money market accounts with a bank. The restricted cash that is used as collateral against the Company’s corporate credit cards is classified as current and the restricted cash to cover the standby letter of credit issued for the Company’s landlord to drawdown on if the facility lease is breached, is classified as non-current (see Note 8).
Concentration of Credit Risk	Concentration of Credit Risk The Company’s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash in bank accounts which at times exceed federally insured limits. The Company attempts to minimize the risks related to cash and cash equivalents by investing in money markets with a broad and diverse range of financial instruments. The investment portfolio is maintained in accordance with the Company’s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Maintenance and repairs are charged to expense as incurred, and costs of improvements are capitalized. Depreciation and amortization is recognized using the straight-line method over the following estimated useful lives: Computer equipment and software 3 years Furniture and fixtures 5 years Machinery and equipment 5 years Leasehold improvements Shorter of lease term or useful life
Impairment of Long Lived Assets and Acquired Intangible Asset	Impairment of Long Lived Assets and Acquired Intangible Asset The Company reviews long-lived assets, including property and equipment, and indefinite-lived intangible, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when the estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. For the year ended December 31, 2015, the Company recorded a $382,000 impairment of property and equipment in research and development within the statement of operations. Acquired in-process research and development (“IPR&D”) represents the fair value assigned to research and development assets that have not reached technological feasibility. The Company reviews amounts capitalized as acquired IPR&D for impairment at least annually, and whenever events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of the acquired IPR&D exceeds its fair value, then the intangible asset is written-down to its fair value. As of December 31, 2015, there have been no such impairments. Once the product candidate derived from the indefinite-lived intangible asset has been developed and commercialized, the useful life will be determined, and the carrying value of the finite-lived asset will be amortized prospectively over that estimated useful life. Alternatively, if the product candidate is abandoned, the carrying value of the intangible will be charged to research and development expense.
Goodwill	Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The Company tests goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that this asset may be impaired. The goodwill test is based on our single operating segment and reporting unit structure. The Company compares the fair value of its reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of the reporting unit, then the Company would need to determine the implied fair value of the reporting unit’s goodwill. If the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then the Company would record an impairment loss equal to the difference. N o goodwill impairment was identified through December 31, 2015.
Convertible Preferred Stock Warrant Liability	Convertible Preferred Stock Warrant Liability The Company classified warrants exercisable for shares of the Company’s Series A and Series B convertible preferred stock as derivative liabilities and adjusted their carrying value to fair value at the end of each reporting period as long as such warrants were outstanding. At the end of each reporting period, changes in the fair value of the convertible preferred stock warrant liability during the period were recorded as a component of other expense, net, in the consolidated statements of operations.
Derivative Liability	Derivative Liability The Company has a derivative liability related to the contingent consideration associated with the acquisition of InteKrin. There were two contingent payments payable upon the achievement of certain events: (i) the completion of the first dosing of a human subject in the first Phase 2 clinical trial for InteKrin, (“Earn-Out Payment”) and (ii) upon the execution of any license, sublicense, development, collaboration, joint venture, partnering or similar agreement between the Company and the third party (“Compound Transaction Payment”). The derivative related to the contingent consideration is accounted for as a liability and remeasured to fair value as of each balance sheet date and the related remeasurement adjustment is recognized as other income (expense), net in the consolidated statements of operations. The Company determined the fair value of the two contingent consideration scenarios (the Earn-Out Payment and the Compound Transaction Payment) using a probability-weighted discounted cash flow approach. A probability-weighted value was determined by summing the probability of achieving a contingent payment threshold by the respective contingent payments. The expected cash flows were discounted at a rate selected to capture the risk of achieving the contingent payment thresholds and earning the contingent payment. This risk is comprised of InteKrin’s continued development, a specific risk factor associated with meeting the contingent consideration threshold and related payout, and counterparty risk associated with the payment of the contingent consideration.
Embedded Derivative Liability	Embedded Derivative Liability The Company recorded derivative instruments related to redemption features embedded within the convertible notes when such notes were outstanding. The embedded derivatives were accounted for as a liability and were remeasured to fair value as of each balance sheet date when such notes were outstanding, with the related remeasurement adjustment being recognized as a component of other income (expense), net in the consolidated statements of operations.
Accrued Research and Development Expenses	Accrued Research and Development Expenses Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research organizations and clinical sites. The Company determines the actual costs through monitoring patient enrollment, discussions with internal personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when persuasive evidence of an arrangement exists; transfer of technology has been completed, services have been performed or products have been delivered; the fee is fixed and determinable; and collection is reasonably assured. For revenue agreements with multiple elements, the Company identifies the deliverables included within the agreement and evaluates which deliverables may represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. Deliverables under the arrangement are a separate unit of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item and delivery or performance of the undelivered items are considered probable and substantially within the Company’s control. The Company determines how to allocate arrangement consideration to identified units of accounting based on the selling price hierarchy provided under the relevant guidance. The selling price used for each unit of accounting is based on vendor-specific objective evidence, if available, third party evidence if vendor-specific objective evidence is not available or estimated selling price if neither vendor-specific nor third-party evidence is available. Management may be required to exercise considerable judgment in determining whether a deliverable is a separate unit of accounting and in estimating the selling prices of identified units of accounting under its agreements. Upfront payments received in connection with licenses of the Company’s technology rights are deferred if facts and circumstances dictate that the license does not have stand-alone value. Such payments are recognized as license revenue over the estimated period of performance that is generally consistent with the terms of the research and development obligations contained in the specific collaboration and license agreement. The Company regularly reviews the estimated period of performance based on the progress made under each arrangement. Amounts received as funding of research and development activities are recognized as revenue if the collaboration arrangement involves the sale of the Company’s research or development services. However, such funding is recognized as a reduction in research and development expense when the Company engages in a research and development project jointly with another entity, with both entities participating in project activities and sharing costs and potential benefits of the arrangement. Payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved, assuming all other revenue recognition criteria are met. A milestones is defined as an event that can only be achieved based on the Company’s performance where there is substantive uncertainty about whether the event will be achieved at the inception of the arrangement. Events that are contingent only on the passage of time or only on counterparty performance are not considered milestones under accounting guidance. The Company’s evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the Company’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the Company’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Other contingent payments in which a portion of the payment is refundable or adjusts based on future performance or non-performance (e.g., through a penalty or claw-back provision) are not considered to relate solely to the Company’s past performance, and therefore, not considered substantive. Non-substantive contingent payments are classified as deferred revenue if they are ultimately expected to result in revenue recognition. The Company recognizes non-substantive contingent payments over the remaining estimated period of performance once the specific objective is achieved. Any portion of the non-substantive contingent payments which may be required to be refunded to the collaborator are not included in deferred revenue and instead are reflected as contingent liability to collaborator on the consolidated balance sheets. Contingent payments associated with the achievement of specific objectives in certain contracts that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are recognized as revenue upon achievement of the objective, as long as there are no undelivered elements remaining and no continuing performance obligations by the Company, assuming all other revenue recognition criteria are met. Revenue from a government contract is recognized in the period during which the related costs are incurred and the related services are rendered, provided that the funds received are not refundable and applicable conditions under the government contract have been met. Funds received in advance are recorded as deferred revenue.
Research and Development Expense	Research and Development Expenses Research and development costs are charged to expenses as incurred. Research and development expenses include, among other costs, salaries and other personnel-related costs, consultant fees, preclinical costs, cost to manufacture drug candidates and clinical supplies, laboratory supplies costs and facility-related costs. Costs incurred under agreements with third parties are charged to expense as incurred in accordance with the specific contractual performance terms of such agreements. Costs of third parties include costs associated with preclinical and clinical support activities. In certain cases, amounts received as reimbursement of research and development activities from the Company’s collaborators are recognized as a reduction in research and development expense when the Company engages in a research and development project jointly with another party, with both parties incurring costs while actively participating in project activities and both parties sharing costs and potential benefits of the arrangement. Costs incurred under the arrangements where the Company provides research services approximate the amount of revenues recorded. Advance payments for goods or services to be received in the future to be utilized in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are received.
Share-Based Compensation	Stock-Based Compensation The Company measures the cost of equity-based service awards based on the grant-date fair value of the award, and recognizes the cost of such awards straight-line over the vesting period. Because non-cash stock compensation expense is based on awards ultimately expected to vest, it is reduced by an estimate for future forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. The Company accounts for equity instruments issued to nonemployees using the fair value approach. These equity instruments consist of stock options and restricted common stock, which are valued using the Black-Scholes option-pricing model. Stock-based compensation expense is recognized as the equity instruments are earned. The measurement of stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest. The Company utilizes the Black-Scholes option-pricing model for estimating fair value of its stock options and restricted stock granted. Option valuation models, including the Black-Scholes option-pricing model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, the expected life of the award, and estimated forfeitures.
Income Taxes	Income Taxes The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had accrued no amounts for interest and penalties related to income tax matters in the Company’s consolidated balance sheets at December 31, 2015 and 2014.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is composed of two components: net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity, but are excluded from net loss. The Company’s other comprehensive loss included foreign currency translation adjustments for the years ended December 31, 2015 and 2014.
Net Loss per Share Attributable to Coherus	Net Loss per Share Attributable to Coherus Basic net loss per share attributable to Coherus is calculated by dividing the net loss attributable to Coherus by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common shares. Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Coherus is the same as diluted net loss per share attributable to Coherus as the inclusion of all potential dilutive common shares would have been anti-dilutive for all periods presented. Shares of founders’ common stock subject to repurchase are excluded from the calculation of weighted average shares as the vesting of such shares is contingent upon continued services being rendered by such holders.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers: Deferral of the Effective Date , the FASB deferred the effective date of ASU 2014-09 for public business entities to fiscal years beginning after December 15, 2017, including interim reporting periods within that reporting period, with early adoption permitted on the original effective date of fiscal years beginning after December 15, 2016 In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern all annual and interim reporting periods thereafter, In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes all annual and interim reporting periods thereafter, In January 2016, the FASB issued ASU No. 2016-1, Recognition and Measurement of Financial Assets and Financial Liabilities. all annual and interim reporting periods thereafter. E In February 2016, the FASB issued ASU No. 2016-2, Leases The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or no material effect is expected on the consolidated financial statements as a result of future adoption.

Basis of Presentation and Sum28

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Revenue by Geographical Region	The following table summarizes revenue by geographic region (in thousands): Year Ended December 31, 2015 2014 2013 United States $ 27,802 $ 28,481 $ 726 Rest of world 2,239 2,625 2,025 Total revenue $ 30,041 $ 31,106 $ 2,751
Summary of Customers Revenue Accounted for 10% or More of Total Revenue	Customers whose collaboration and license revenue accounted for 10% or more of total revenues were as follows: Year Ended December 31, 2015 2014 2013 Daiichi Sankyo - related party (1) * * 74 % Baxalta 93 % 92 % 26 % * less than 10% (1) Represents revenue from Daiichi Sankyo through November 12, 2014 as a related party, a holder of more than 10% of our common stock until the closing of our IPO.
Schedule of Estimated Useful Lives of Property Plant and Equipment	Property and equipment are stated at cost less accumulated depreciation and amortization. Maintenance and repairs are charged to expense as incurred, and costs of improvements are capitalized. Depreciation and amortization is recognized using the straight-line method over the following estimated useful lives: Computer equipment and software 3 years Furniture and fixtures 5 years Machinery and equipment 5 years Leasehold improvements Shorter of lease term or useful life

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Financial Assets and Liabilities Measured on a Recurring Basis	Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements are as follows (in thousands): Fair Value Measurements December 31, 2015 Total Level 1 Level 2 Level 3 Assets: Money market funds $ 157,784 $ 157,784 $ — $ — Restricted cash (money market funds) 845 845 — — Total financial assets $ 158,629 $ 158,629 $ — $ — Liabilities: Contingent consideration $ 1,245 $ — $ — $ 1,245 Fair Value Measurements December 31, 2014 Total Level 1 Level 2 Level 3 Assets: Money market funds $ 147,952 $ 147,952 $ — $ — Restricted cash (money market funds) 60 60 — — Total financial assets $ 148,012 $ 148,012 $ — $ — Liabilities: Contingent consideration $ 6,495 $ — $ — $ 6,495
Contingent Consideration | Fair Value Measurements Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Financial Assets and Liabilities Measured on a Recurring Basis	The following table sets forth a summary of changes in the estimated fair value of the contingent consideration (in thousands): Balance as of February 12, 2014 (acquisition date) $ 1,310 Change in fair value of the contingent consideration liability 5,185 Balance as of December 31, 2014 6,495 Change in fair value of the contingent consideration liability 4,599 Fair value of Earn-Out Payment settled in common stock on March 6, 2015 (9,849 ) Balance as of December 31, 2015 $ 1,245

Balance Sheet Components (Table

Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Prepaid Assets	Prepaid assets are as follows (in thousands): December 31, December 31, 2015 2014 Prepaid clinical, material, manufacturing and other - related parties (see Note 15) $ 10,901 $ 5,990 Prepaid clinical, material and manufacturing 21,191 12,149 Prepaid other 2,651 2,346 Prepaid assets $ 34,743 $ 20,485
Schedule of Property and Equipment, Net	Property and equipment, net are as follows (in thousands): December 31, December 31, 2015 2014 Machinery and equipment $ 7,809 $ 4,317 Computer equipment and software 1,276 286 Furniture and fixtures 596 288 Leasehold improvements 4,343 399 Construction in progress — 474 Total property and equipment 14,024 5,764 Accumulated depreciation and amortization (3,520 ) (1,292 ) Property and equipment, net $ 10,504 $ 4,472
Schedule of Accrued Liabilities	Accrued liabilities are as follows (in thousands): December 31, December 31, 2015 2014 Accrued clinical, manufacturing and other - related parties (see Note 15) $ 6,122 $ 2,997 Accrued clinical and manufacturing 11,681 2,396 Accrued compensation 4,666 3,435 Accrued professional and consulting fees 446 252 Accrued other 1,218 2,151 Accrued liabilities $ 24,133 $ 11,231

Collaboration and License Agr31

Collaboration and License Agreement (Tables)	12 Months Ended
	Dec. 31, 2015
Collaboration And License Agreements [Abstract]
Schedule of Revenue Related to Collaboration and License Agreement	The Company recognized revenue related to the collaboration and license agreements for the periods presented as follows (in thousands): Year Ended December 31, 2015 2014 2013 Baxalta $ 27,802 $ 28,481 $ 726 Daiichi Sankyo - related party (1) 2,239 1,893 2,025 Total collaboration and license revenue $ 30,041 $ 30,374 $ 2,751 (1) Represents revenue from Daiichi Sankyo through November 12, 2014 as a related party, a holder of more than 10% of our common stock until the closing of our initial public offering (“IPO”).

Acquisition of InteKrin Thera32

Acquisition of InteKrin Therapeutics, Inc. (Tables)	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Fair Value of Assets Acquired and Liabilities Assumed	The following table summarizes the original fair value of the assets acquired and liabilities assumed (in thousands): Cash $ 2,335 Prepaid and other assets 107 Accounts payable and other current liabilities (1,027 ) In-process research and development 2,620 Goodwill 943 Total $ 4,978

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for all the Company's Facility Leases	The future minimum lease payments for these facilities as of December 31, 2015 are as follows (in thousands): Year ending December 31, 2016 $ 1,692 2017 1,276 2018 1,669 2019 1,719 2020 and thereafter 5,315 Total minimum lease payments $ 11,671

Convertible Preferred Stock W34

Convertible Preferred Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2015
Convertible Preferred Stock Warranty Liability | Fair Value Measurements Recurring Basis
Changes in Estimated Fair Value of Convertible Preferred Stock Warrants	The following table sets forth a summary of the changes in the estimated fair value of the convertible preferred stock warrants for the year ended December 31, 2014 (in thousands): December 31, 2014 Balance, beginning of year $ 24,251 Warrants issued in connection with notes payable — Initial fair value of the warrants issued in excess of debt proceeds recognized in other income (expense), net — Warrants exercised (40,150 ) Change in fair value of convertible preferred stock warrant liability 15,899 Balance, end of year $ —

Stock Option Plans and Stock-35

Stock Option Plans and Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Summary of Non-Vested Restricted Stock	A summary of the Company’s non-vested restricted stock for the periods is as follows: Number of Shares Non-vested as of December 31, 2014 21,245 Vested (21,245 ) Non-vested as of December 31, 2015 —
Schedule of Stock-Based Compensation Expense	The stock-based compensation expense recorded related to options granted to employees was as follows (in thousands): Year Ended December 31, 2015 2014 2013 Research and development $ 6,460 $ 1,580 $ 431 General and administrative 8,289 3,934 309 $ 14,749 $ 5,514 $ 740
Summary of Option Activities under 2014 and 2010 Plans	The following table sets forth the summary of option activities under the 2014 and 2010 Plans: Options Outstanding Shares Available for Grant Number of Options Weighted-Average Exercise Balances at December 31, 2014 2,652,500 5,770,307 $ 2.909 Authorized 1,330,319 — — Granted - at fair value (3,217,313 ) 3,217,313 28.020 Exercised — (861,137 ) 1.660 Forfeited 317,641 (317,641 ) 15.066 Balances at December 31, 2015 1,083,147 7,808,842 $ 12.898
Summary of Additional Information Related to Status of Options	Additional information related to the status of options as of December 31, 2015 is summarized as follows: Number of Options Weighted- Average Exercise Price Weighted- Average Contractual Terms (Years) Aggregate Intrinsic Value (in thousands) Options outstanding 7,808,842 $ 12.898 8.27 $ 94,220 Options vested and expected to vest 7,747,817 $ 12.839 8.26 $ 93,860 Options vested and exercisable 3,054,854 $ 4.956 7.34 $ 56,696
Schedule of Weighted Average Assumptions Used to Value Options Granted to Employees	The weighted average assumptions used to value options granted to employees under the Plan during the years ended December 31, 2015, 2014 and 2013 were as follows: Year Ended December 31, 2015 2014 2013 Expected term (years) 6.00 6.50 5.51 Expected volatility 78 % 99 % 108 % Risk-free interest rate 1.62 % 2.05 % 1.23 % Expected dividend yield 0 % 0 % 0 %
Restricted Common Stock (Founders Shares)
Schedule of Stock-Based Compensation Expense	The stock-based compensation expense recorded related to the founder’s shares was as follows (in thousands): Year Ended December 31, 2015 2014 2013 Research and development $ 9 $ 1,547 $ 227 General and administrative — 4 1,054 $ 9 $ 1,551 $ 1,281

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Reconciliation of Statutory U.S. Federal Rate	A reconciliation of the statutory U.S. federal rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2015 2014 2013 Percent of pre-tax income: U.S. federal statutory income tax rate 34.00 % 34.00 % 34.00 % State taxes, net of federal benefit 0.70 (1.65 ) 3.97 Permanent items (1.25 ) (10.80 ) (12.40 ) Research and development credit 2.46 3.11 4.53 Net operating loss (0.01 ) 0.01 — InteKrin purchase price allocation — 0.73 — Other 0.09 0.02 — Change in valuation allowance (35.99 ) (25.42 ) (30.10 ) Effective income tax rate — % — % — %
Components of Net Deferred Tax Assets	Significant components of the Company’s net deferred tax assets as of December 31, 2015 and 2014 consist of the following (in thousands): December 31, 2015 2014 Net operating loss carryforwards $ 91,334 $ 34,463 Research and development credits 12,980 6,032 Depreciation and amortization 778 854 Stock-based compensation 5,111 1,428 Other accruals 2,236 940 Deferred revenue 23,237 12,762 Gross deferred tax assets 135,676 56,479 In-process research and development (891 ) (892 ) Gross deferred tax liabilities (891 ) (892 ) Total net deferred tax asset 134,785 55,587 Less valuation allowance (134,785 ) (55,587 ) Net deferred tax assets $ — $ —
Reconciliation of Unrecognized Tax Benefits	A reconciliation of the Company’s unrecognized tax benefits for the years ended December 31, 2015 and 2014 is as follows (in thousands): Year Ended December 31, 2015 2014 2013 Balance at beginning of year $ 3,816 $ 749 $ 73 Additions based on tax positions related to current year 3,633 861 319 Additions for tax positions of prior years 3,156 2,206 357 Balance at end of year $ 10,605 $ 3,816 $ 749

Net Loss Per Share Attributab37

Net Loss Per Share Attributable to Coherus (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Share Attributable to Coherus	The following table sets forth the computation of the basic and diluted net loss per share attributable to Coherus (in thousands, except share and per share data): Years Ended December 31, 2015 2014 2013 Numerator: Net loss attributable to Coherus $ (223,260 ) $ (87,133 ) $ (53,635 ) Denominator: Weighted-average common shares outstanding 37,125,617 8,520,100 4,828,214 Less: weighted-average unvested common shares subject to repurchase (1) (3,609 ) (333,571 ) (1,496,194 ) Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted 37,122,008 8,186,529 3,332,020 Net loss per share attributable to Coherus, basic and diluted $ (6.01 ) $ (10.64 ) $ (16.10 ) (1) Shares were excluded as such shares represent restricted common stock (founders’ shares) which is vesting contingently upon the holders’ continued services to the Company.
Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net Loss Per Share Attributable to Coherus	The following outstanding dilutive potential shares have been excluded from the calculation of diluted net loss per share attributable to Coherus due to their anti-dilutive effect: Outstanding as of December 31, 2015 2014 2013 Stock options outstanding 7,808,842 5,770,307 3,047,396 Convertible preferred stock — — 9,153,906 Convertible preferred stock warrants — — 4,638,644 Total 7,808,842 5,770,307 16,839,946

Supplementary Data - Quarterl38

Supplementary Data - Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following table presents certain unaudited consolidated quarterly financial information for each of the quarters ended December 31, 2015 and 2014: 2015 Quarter End (in thousands, except per share data) March 31 June 30 September 30 December 31 Total revenue $ 5,810 $ 6,866 $ 7,167 $ 10,198 Total operating expenses 42,558 65,761 78,384 62,405 Net loss (40,839 ) (59,034 ) (71,485 ) (52,580 ) Net loss attributable to Coherus (40,725 ) (58,810 ) (71,334 ) (52,391 ) Net loss per share attributable to Coherus, basic and diluted (1.22 ) (1.56 ) (1.86 ) (1.35 ) 2014 Quarter End March 31 June 30 September 30 December 31 Total revenue $ 3,596 $ 4,965 $ 16,052 $ 6,493 Total operating expenses 17,357 22,903 22,475 33,053 Net loss (25,170 ) (25,070 ) (7,914 ) (29,023 ) Net loss attributable to Coherus (25,170 ) (24,957 ) (7,872 ) (29,134 ) Net loss per share attributable to Coherus, basic and diluted (6.04 ) (5.96 ) (1.79 ) (1.47 )

Organization and Operations - A

Organization and Operations - Additional Information (Details) $ in Thousands	1 Months Ended	12 Months Ended
	Feb. 29, 2016USD ($)	Dec. 31, 2015USD ($)Segments	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2012USD ($)
Organization And Operations [Line Items]
Number of operating segments | Segments		1
Accumulated deficit		$ 409,985	$ 186,725
Cash and cash equivalents		$ 158,226	$ 150,392	$ 39,554	$ 14,548
Subsequent Event | 8.2% Senior Convertible Notes Due 2022
Organization And Operations [Line Items]
Aggregate principal amount	$ 100,000
Convertible notes, interest rate	8.20%
Debt instrument maturity date	Mar. 31, 2022

Basis of Presentation and Sum40

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2015USD ($)Segments	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Foreign exchange loss	$ 386,000		$ 34,000
Foreign exchange gain		$ 671,000
Number of reportable segment | Segments	1
Number of operating segments | Segments	1
Deferred offering costs	$ 137,000	0
Income tax examination, description	less than a 50%
Unrecognized tax benefits, interest and penalties accrued related to income tax matters	$ 0	$ 0
InteKrin Therapeutics Inc
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Impairment of goodwill	0
InteKrin Therapeutics Inc | In Process Research and Development
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Impairment of property and equipment	382,000
Impairment of intangible assets excluding goodwill	$ 0
RUSSIA | Coherus Intermediate Corp, InteKrin Therapeutics, Inc.
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Controlling interest, ownership percentage by parent	82.50%

Basis of Presentation and Sum41

Basis of Presentation and Summary of Significant Accounting Policies - Summary of Revenue by Geographical Region (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenue	$ 10,198	$ 7,167	$ 6,866	$ 5,810	$ 6,493	$ 16,052	$ 4,965	$ 3,596	$ 30,041	$ 31,106	$ 2,751
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenue									27,802	28,481	726
Rest of World
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenue									$ 2,239	$ 2,625	$ 2,025

Basis of Presentation and Sum42

Basis of Presentation and Summary of Significant Accounting Policies - Summary of Customers Revenue Accounted for 10% or More of Total Revenue (Details) - Collaboration and License Revenue - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Daiichi Sankyo - Related Party
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Percentage of total revenues by single customer			74.00%
Baxalta
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Percentage of total revenues by single customer	93.00%	92.00%	26.00%

Basis of Presentation and Sum43

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Revenue Related to Collaboration and License Agreements (Parenthetical) (Details)	Nov. 12, 2014
Daiichi Sankyo - Related Party
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Percentage of equity interest held by related party, minimum	10.00%

Basis of Presentation and Sum44

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2015
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Estimated useful lives	3 years
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Estimated useful lives	5 years
Machinery and Equipment
Property Plant And Equipment [Line Items]
Estimated useful lives	5 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Estimated useful lives, description	Shorter of lease term or useful life

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	Mar. 06, 2015	Jan. 08, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfers from Level 1 to Level 3			$ 0	$ 0
Transfers from Level 3 to Level 1			0	0
Remeasurement of contingent consideration			4,599,000	5,185,000
Other expense, net			4,838,000	18,595,000	$ 12,349,000
InteKrin Therapeutics Inc
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Business acquisition, number of shares issued	358,384
Business acquisition, share price	$ 27.48
Business acquisition, cash payment	$ 1,000	$ 1,485
Business acquisition, value of shares issued	9,800,000
Additional fair value of earn-out payment to other expense	$ 4,100,000
Other expense, net			4,100,000	5,000,000
Other Expense, Net
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Remeasurement of contingent consideration			$ 460,000	$ 235,000
Fair Value Measurements Recurring Basis | Level 3 | Contingent Consideration
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected probability of earn-out payment occurrence				98.00%
Discount rate			25.00%	25.00%
Counterparty credit risk given the cash payment			6.00%	6.00%
Fair Value Measurements Recurring Basis | Money Market Funds | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Unrealized gains and losses on investments			$ 0

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value Measurements Recurring Basis - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 158,629	$ 148,012
Contingent Consideration
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities	1,245	6,495
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	158,629	148,012
Level 3 | Contingent Consideration
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities	1,245	6,495
Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	157,784	147,952
Money Market Funds | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	157,784	147,952
Restricted Cash (Money Market Funds)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	845	60
Restricted Cash (Money Market Funds) | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 845	$ 60

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in the Estimated Fair Value of Contingent Consideration (Details) - USD ($) $ in Thousands	11 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Fair value of Earn-Out Payment settled in common stock on March 6, 2015		$ (9,849)
Contingent Consideration
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 1,310	6,495
Change in fair value of the contingent consideration liability	5,185	4,599
Fair value of Earn-Out Payment settled in common stock on March 6, 2015		(9,849)
Ending balance	$ 6,495	$ 1,245

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Prepaid Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Schedule Of Prepaid Assets [Line Items]
Prepaid assets	$ 34,743	$ 20,485
Prepaid Clinical, Material, Manufacturing and Other - Related Parties
Schedule Of Prepaid Assets [Line Items]
Prepaid assets	10,901	5,990
Prepaid Clinical, Material and Manufacturing
Schedule Of Prepaid Assets [Line Items]
Prepaid assets	21,191	12,149
Prepaid Other
Schedule Of Prepaid Assets [Line Items]
Prepaid assets	$ 2,651	$ 2,346

Balance Sheet Components - Sc49

Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property Plant And Equipment [Line Items]
Total property and equipment	$ 14,024	$ 5,764
Accumulated depreciation and amortization	(3,520)	(1,292)
Property and equipment, net	10,504	4,472
Machinery and Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	7,809	4,317
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Total property and equipment	1,276	286
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Total property and equipment	596	288
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment	$ 4,343	399
Construction in Progress
Property Plant And Equipment [Line Items]
Total property and equipment		$ 474

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property Plant And Equipment [Abstract]
Depreciation and amortization	$ 1,869	$ 674	$ 404
Leasehold improvements related to new headquarters	$ 3,100

Balance Sheet Components - Sc51

Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Payables And Accruals [Abstract]
Accrued clinical, manufacturing and other - related parties	$ 6,122	$ 2,997
Accrued clinical and manufacturing	11,681	2,396
Accrued compensation	4,666	3,435
Accrued professional and consulting fees	446	252
Accrued other	1,218	2,151
Accrued liabilities	$ 24,133	$ 11,231

Collaboration and License Agr52

Collaboration and License Agreement - Schedule of Revenue Related to Collaboration and License Agreements (Details) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
		Aug. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration and license revenue			$ 30,041	$ 30,374	$ 2,751
Baxalta License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration and license revenue		$ 30,000	27,802	28,481	726
Daiichi Sankyo - Related Party
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration and license revenue	[1]		$ 2,239	$ 1,893	$ 2,025
[1]	Represents revenue from Daiichi Sankyo through November 12, 2014 as a related party, a holder of more than 10% of our common stock until the closing of our initial public offering (“IPO”).

Collaboration and License Agr53

Collaboration and License Agreement - Schedule of Revenue Related to Collaboration and License Agreements (Parenthetical) (Details)	Nov. 12, 2014
Daiichi Sankyo - Related Party
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of equity interest held by related party, minimum	10.00%

Collaboration and License Agr54

Collaboration and License Agreement - Additional Information (Details) - USD ($)		Sep. 10, 2015	Jun. 30, 2015	Feb. 28, 2014	Jan. 31, 2014	Aug. 31, 2013	Jun. 30, 2013	Jan. 31, 2012	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Apr. 30, 2015
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from issuance of convertible preferred stock, net of issuance costs												$ 54,660,000
Advance payments under license agreement										$ 1,330,000	$ 1,330,000	1,192,000
Deferred revenue, current										49,621,000	49,621,000	22,800,000
Deferred revenue, non-current										45,338,000	45,338,000	39,899,000
Collaboration and license revenue											30,041,000	30,374,000	$ 2,751,000
Contingent liability to collaborator										66,255,000	66,255,000	27,650,000
Baxalta License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue										92,000,000	92,000,000
Initial term of agreement						10 years
Renewal term of agreement						3 years
Estimated period of performance upfront fee						3 years
Deferred revenue, current										48,000,000	48,000,000
Deferred revenue, non-current										44,000,000	44,000,000
Collaboration and license revenue						$ 30,000,000					27,802,000	28,481,000	726,000
Contingent payment receivable						$ 120,000,000
Prior written notice of termination of license agreement						18 months
Contingent payment development related expenses						$ 56,000,000
Contingent payments refundable, percentage						50.00%
Expiration or termination of license agreement						10 years
Increase in license agreement non-substantive contingent milestone receivable				$ 5,300,000
Contingent liability to collaborator										66,300,000	66,300,000
Baxalta License Agreement | Private Placement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock, shares issued		390,167
Issuance price per share of convertible preferred stock		$ 25.63
Gross proceeds from issuance of common stock		$ 10,000,000
Baxalta License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent payment receivable				221,300,000		$ 216,000,000
Baxalta License Agreement | Maximum | Clinical Development Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent payment receivable				101,300,000		96,000,000
Baxalta License Agreement | Maximum | Regulatory Milestone Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent payment receivable				$ 120,000,000		$ 120,000,000
Baxalta Second Amendment
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue										$ 61,400,000	$ 61,400,000
Contingent payment receivable														$ 130,000,000
Contingent payments refundable, percentage										50.00%
Expiration of license agreement											2023-08
Milestone Payment Received										$ 100,000,000
Contingent liability to collaborator										38,600,000	$ 38,600,000
Value of shares of common stock to purchase under agreement														10,000,000
Baxalta Second Amendment | Private Placement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock, shares issued		390,167
Issuance price per share of convertible preferred stock		$ 25.63
Gross proceeds from issuance of common stock		$ 10,000,000
Baxalta Second Amendment | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent payment receivable														335,300,000
Baxalta Second Amendment | Maximum | Clinical Development Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent payment receivable														215,300,000
Baxalta Second Amendment | Maximum | Regulatory Milestone Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent payment receivable														$ 120,000,000
Baxter License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue												58,400,000
Deferred revenue, current												21,200,000
Deferred revenue, non-current												37,200,000
Collaboration and license revenue									$ 10,000,000
Contingent liability to collaborator												27,700,000
Daiichi Sankyo - Related Party
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue								$ 10,000,000		2,800,000	$ 2,800,000	4,300,000
Initial term of agreement								10 years
Renewal term of agreement								3 years
Estimated period of performance upfront fee											3 years
License agreement finalized period							90 days
Percentage of budgeted cost, total							33.00%
Percentage of cost of comparator drug							100.00%
Minimum percentage of clinical trial cost			20.00%		20.00%
Advance payments under license agreement										1,300,000	$ 1,300,000	1,200,000
Deferred revenue, current										1,500,000	1,500,000	1,600,000
Deferred revenue, non-current										$ 1,300,000	1,300,000	2,700,000
Research and development											16,100,000	7,100,000	1,300,000
Collaboration and license revenue	[1]										$ 2,239,000	$ 1,893,000	$ 2,025,000
Series B Convertible Preferred Stock | Daiichi Sankyo - Related Party
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Convertible preferred stock, shares issued								2,867,426
Convertible preferred stock, par value								$ 6.9749
Proceeds from issuance of convertible preferred stock, net of issuance costs								$ 18,100,000
Convertible Preferred Stock | Daiichi Sankyo - Related Party
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Convertible preferred stock								$ 18,100,000
[1]	Represents revenue from Daiichi Sankyo through November 12, 2014 as a related party, a holder of more than 10% of our common stock until the closing of our initial public offering (“IPO”).

Acquisition of InteKrin Thera55

Acquisition of InteKrin Therapeutics, Inc. - Additional Information (Details) $ / shares in Units, RUB in Millions	Mar. 06, 2015USD ($)$ / sharesshares	Jan. 08, 2014USD ($)$ / sharesshares	Feb. 28, 2014USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2015USD ($)Agreementshares	Dec. 31, 2014USD ($)	Dec. 31, 2014RUB	Mar. 31, 2015USD ($)	Mar. 31, 2015RUB	Mar. 31, 2014RUB	Feb. 12, 2014USD ($)
Business Acquisition [Line Items]
Business acquisition, contingent consideration				$ 6,500,000		$ 6,500,000
Number of contingent consideration for potential payments | Agreement					2
Contingent consideration, probability of completion					75.00%
Fair value inputs contingent probability					7.50%
Remeasurement of contingent consideration					$ 4,599,000	5,185,000
Contingent Consideration
Business Acquisition [Line Items]
Fair value of contingent consideration liability				6,495,000	1,245,000	6,495,000					$ 1,310,000
Change in fair value of the contingent consideration liability				5,185,000	$ 4,599,000
Maximum | Year One
Business Acquisition [Line Items]
Percent of administrative fees received					60.00%
Minimum | Year Three
Business Acquisition [Line Items]
Percent of administrative fees received					10.00%
Contingent Consideration Earn-out Payment
Business Acquisition [Line Items]
Fair value of contingent consideration											800,000
Contingent Consideration Compound Transaction Payment
Business Acquisition [Line Items]
Fair value of contingent consideration											$ 500,000
Series B Convertible Preferred Stock
Business Acquisition [Line Items]
Business acquisition, number of shares issued | shares					358,384
InteKrin Therapeutics Inc
Business Acquisition [Line Items]
Business acquisition, date of acquisition agreement		Jan. 8, 2014
Business acquisition, description of acquired entity					All of the outstanding shares of InteKrin and its 82.5% majority owned subsidiary, InteKrin Russia
Business acquisition, effective date of acquisition		Feb. 12, 2014
Business Combination Consideration Transferred1		$ 5,000,000	$ 5,000,000
Business combination, reason for business combination					Additionally, the acquisition of InteKrin was a strategic transaction to obtain funding from new investors.
Business acquisition, number of shares issued | shares	358,384
Business acquisition, cash payment	$ 1,000	1,485
Business acquisition, contingent consideration		$ 1,300,000
Business acquisition, share price | $ / shares	$ 27.48
Fair value of contingent consideration	$ 9,800,000
Impairment of goodwill					$ 0
Government contract amount						2,600,000	RUB 147.9
Deferred revenue				$ 28,000,000		28,000,000		$ 162,000	RUB 11.8	RUB 12
Deferred revenue, recognized						732,000	40
InteKrin Therapeutics Inc | Two Thousand Fourteen
Business Acquisition [Line Items]
Government contract amount | RUB							40
InteKrin Therapeutics Inc | Two Thousand Fifteen
Business Acquisition [Line Items]
Government contract amount | RUB							RUB 39.4
InteKrin Therapeutics Inc | In Process Research and Development
Business Acquisition [Line Items]
Estimated acquisition represents fair value					2,600,000
Impairment of intangible assets excluding goodwill					$ 0
InteKrin Therapeutics Inc | Series B Convertible Preferred Stock
Business Acquisition [Line Items]
Business acquisition, number of shares issued | shares		716,645
Business acquisition, value of shares issued		$ 2,700,000
Business acquisition, fair value method					PWERM
InteKrin Therapeutics Inc | Series B Convertible Preferred Stock
Business Acquisition [Line Items]
Business acquisition, number of shares issued | shares		243,841
Business acquisition, value of shares issued		$ 1,000,000
InteKrin Therapeutics Inc | General and Administrative Expense
Business Acquisition [Line Items]
Business acquisition costs, legal expenses						$ 134,000
InteKrin Therapeutics Inc | PWERM | Series B Convertible Preferred Stock
Business Acquisition [Line Items]
Business acquisition, share price | $ / shares		$ 3.8174
Coherus Intermediate Corp, InteKrin Therapeutics, Inc. | RUSSIA | InteKrin Therapeutics Inc
Business Acquisition [Line Items]
Controlling interest, ownership percentage by parent		82.50%

Acquisition of InteKrin Thera56

Acquisition of InteKrin Therapeutics, Inc. - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net [Abstract]
Cash		$ 2,335
Prepaid and other assets		107
Accounts payable and other current liabilities		(1,027)
In-process research and development		2,620
Goodwill	$ 943	943
Total		$ 4,978

Debt Obligations - Additional I

Debt Obligations - Additional Information (Details) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended
	May. 31, 2014	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 09, 2013	Sep. 30, 2013
Debt Instrument [Line Items]
Preferred stock, shares issued			0	0
Other income (expense), net			$ (4,838,000)	$ (18,595,000)	$ (12,349,000)
Reduction to accrued interest and derivative liability					0
Gains on extinguishment of debt				2,048,000
Total interest expense related to accrued interest and amortization of debt discount				$ 3,900,000	$ 4,800,000
Warrant
Debt Instrument [Line Items]
Fair value of embedded derivative liability		$ 4,100,000
Reduction of debt		$ 0
Series C Convertible Preferred Stock
Debt Instrument [Line Items]
Preferred stock, shares issued	5,488,892
Issuance of convertible preferred stock shares upon conversion of convertible promissory notes, Shares	1,058,089			1,058,089
Convertible Preferred Stock
Debt Instrument [Line Items]
Warrant exercise price		$ 0.0167
Series B Convertible Preferred Stock
Debt Instrument [Line Items]
Conversion of cash payments outstanding principal percentage					400.00%
Reduction to conversion of cash payments outstanding principal percentage					100.00%
Stock issued for warrant exercised						4,279,620
Convertible Debt
Debt Instrument [Line Items]
Aggregate principal amount							$ 10,000,000
Accrued interest							8.00%
Debt instrument maturity date			Jul. 15, 2014
Bridge Loan
Debt Instrument [Line Items]
Percentage on shares issuable to warrants		300.00%
Initial fair value of the warrants		$ 13,600,000
Other income (expense), net		3,600,000
Debt instrument, unamortized discount		10,000,000
Beneficial conversion feature		$ 0
Bridge loans and related accrued interest	$ 10,600,000
Intrinsic value on loans extinguishment	$ 3,900,000
Gains on extinguishment of debt				$ 2,000,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	Jul. 06, 2015USD ($)ft²	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Purchase Commitment Excluding Longterm Commitment [Line Items]
Current lease, leased date		Sep. 26, 2011
Rent expense		$ 1,800,000	$ 800,000	$ 400,000
Liability
Purchase Commitment Excluding Longterm Commitment [Line Items]
Guarantor liability		$ 50,000
New Lease Agreement
Purchase Commitment Excluding Longterm Commitment [Line Items]
Current lease, commenced date		Dec. 1, 2015
Annual base rent for the first year of lease term	$ 1,600,000
One-time improvement allowance	1,200,000
New Lease Agreement | Letter of Credit
Purchase Commitment Excluding Longterm Commitment [Line Items]
Letter of credit amount	800,000	$ 800,000
Letter of credit amount at the end of lease term	300,000
New Lease Agreement | Maximum
Purchase Commitment Excluding Longterm Commitment [Line Items]
Rent for the final year of lease term	$ 1,900,000
New Lease Agreement | Hudson 333 Twin Dolphin Plaza, LLC
Purchase Commitment Excluding Longterm Commitment [Line Items]
Area of office space leased | ft²	27,532
Seventh Amendment to Current Lease
Purchase Commitment Excluding Longterm Commitment [Line Items]
Lease termination description		The Seventh Amendment provided early termination of the Current Lease which was effective in December 2015 when the New Leased commenced
Lease expiration date		Apr. 30, 2017
Corporate Headquarters Lease
Purchase Commitment Excluding Longterm Commitment [Line Items]
Lease expiration date		Nov. 30, 2022
Leases extended expiration period		3 years
Camarillo Laboratory Lease
Purchase Commitment Excluding Longterm Commitment [Line Items]
Lease expiration date		Jun. 30, 2017
Leases extended expiration period		3 years
CMOs
Purchase Commitment Excluding Longterm Commitment [Line Items]
Contractual commitment due within a year		$ 14,500,000
Medpace Inc
Purchase Commitment Excluding Longterm Commitment [Line Items]
Minimum fee commitment		$ 35,000,000
Prior notification period of contract termination		30 days

Commitments and Contingencies59

Commitments and Contingencies - Schedule of Future Minimum Lease Payments for all the Company's Facility Leases (Details) $ in Thousands	Dec. 31, 2015USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,016	$ 1,692
2,017	1,276
2,018	1,669
2,019	1,719
2020 and thereafter	5,315
Total minimum lease payments	$ 11,671

Convertible Preferred Stock W60

Convertible Preferred Stock Warrants - Additional Information (Details) - USD ($)

1 Months Ended

2 Months Ended

9 Months Ended

12 Months Ended

Nov. 30, 2014

May. 31, 2014

Apr. 30, 2014

Jun. 30, 2012

May. 31, 2014

Sep. 30, 2014

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Dec. 09, 2013

Sep. 30, 2013

Jan. 31, 2012

Dec. 31, 2011

Mar. 31, 2011

Class Of Stock [Line Items]

Proceeds from issuance of convertible preferred stock upon exercise of warrants

$ 131,000

Proceeds from issuance of convertible preferred stock, net of issuance costs

54,660,000

Other income (expense), net

$ (4,838,000)

(18,595,000)

$ (12,349,000)

Change in fair value of Warrant liability

15,900,000

$ 8,900,000

Reclassification of fair value of convertible preferred stock warrants to preferred stock upon exercise

40,150,000

Convertible Preferred Stock Warranty Liability

Class Of Stock [Line Items]

Convertible preferred stock warrant liability

0

Bridge Loan

Class Of Stock [Line Items]

Initial fair value of the warrants

$ 13,600,000

Other income (expense), net

$ 3,600,000

Series A Convertible Preferred Stock

Class Of Stock [Line Items]

Stock issued for warrant exercised

62,251

Reclassification of fair value of convertible preferred stock warrants to preferred stock upon exercise

1,000,000

Series B Convertible Preferred Stock

Class Of Stock [Line Items]

Stock issued for warrant exercised

123,051

4,451,662

4,451,662

57,347

4,451,662

Proceeds from issuance of convertible preferred stock upon exercise of warrants

$ 74,000

$ 74,000

Proceeds from issuance of convertible preferred stock, net of issuance costs

$ 1,000

Reclassification of fair value of convertible preferred stock warrants to preferred stock upon exercise

39,300,000

Series B Convertible Preferred Stock | Bridge Loan

Class Of Stock [Line Items]

Stock issued for warrant exercised

4,279,620

4,279,620

4,279,620

2011 Warrants A | Series A Convertible Preferred Stock

Class Of Stock [Line Items]

Stock issued for warrant exercised

62,251

63,923

Convertible preferred stock conversion price

$ 1.2503

Proceeds from issuance of convertible preferred stock upon exercise of warrants

$ 55,000

Two Thousand And Eleven Warrants B

Class Of Stock [Line Items]

Warrant exercise price

$ 0.0167

Two Thousand And Eleven Warrants B | Series B Convertible Preferred Stock

Class Of Stock [Line Items]

Stock issued for warrant exercised

123,051

172,042

172,042

352,448

Proceeds from issuance of convertible preferred stock upon exercise of warrants

$ 2,000

$ 3,000

2013 Warrants | Bridge Loan

Class Of Stock [Line Items]

Warrant exercise price

$ 0.0167

Initial fair value of the warrants

$ 13,600,000

Aggregate principal amount

$ 10,000,000

Other income (expense), net

$ 3,600,000

2013 Warrants | Series B Convertible Preferred Stock | Bridge Loan

Class Of Stock [Line Items]

Stock issued for warrant exercised

4,279,620

4,279,620

4,279,620

Proceeds from issuance of convertible preferred stock upon exercise of warrants

$ 71,000

Convertible Preferred Stock W61

Convertible Preferred Stock Warrants - Changes in Estimated Fair Value of Convertible Preferred Stock Warrants (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Initial fair value of the embedded derivative issued in excess of debt proceeds recognized in other income (expense), net		$ 3,669
Remeasurement of convertible preferred stock warrant and embedded derivative liabilities	$ 15,899	4,557
Convertible Preferred Stock Warranty Liability
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending balance	0
Convertible Preferred Stock Warranty Liability | Level 3
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	24,251
Warrants exercised	(40,150)
Remeasurement of convertible preferred stock warrant and embedded derivative liabilities	$ 15,899
Ending balance		$ 24,251

Common Stock Warrants - Additio

Common Stock Warrants - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended
	Mar. 31, 2014	Nov. 12, 2014
Class Of Warrant Or Right [Line Items]
Common stock, per share value	$ 5.73
Employee Warrants
Class Of Warrant Or Right [Line Items]
Common stock, per share value	4.95
Consultant Warrants
Class Of Warrant Or Right [Line Items]
Common stock, per share value	$ 5.42
Common Stock
Class Of Warrant Or Right [Line Items]
Issued warrants to purchase shares of common stock	553,274
Common stock, exercise price	$ 1.667
Initial fair value of the warrants	$ 2,700
Common Stock | IPO
Class Of Warrant Or Right [Line Items]
Issued warrants to purchase shares of common stock		491,580
Common Stock | Employee Warrants
Class Of Warrant Or Right [Line Items]
Initial fair value of the warrants	2,600
Common Stock | Consultant Warrants
Class Of Warrant Or Right [Line Items]
Initial fair value of the warrants	$ 144
Warrant
Class Of Warrant Or Right [Line Items]
Dividend yield	0.00%
Fair value assumptions, exercise price	$ 1.667
Warrant | Employee Warrants
Class Of Warrant Or Right [Line Items]
Expected volatility	93.00%
Risk-free interest rate	1.74%
Expected terms	5 years
Warrant | Consultant Warrants
Class Of Warrant Or Right [Line Items]
Expected volatility	96.00%
Risk-free interest rate	2.73%
Expected terms	10 years
Warrant Issued For Past Services | Research and Development Expense
Class Of Warrant Or Right [Line Items]
Stock-based compensation expense	$ 1,300
Warrant Issued For Past Services | General and Administrative Expense
Class Of Warrant Or Right [Line Items]
Stock-based compensation expense	$ 1,400

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) - Additional Information (Details) $ / shares in Units, $ in Thousands	Sep. 10, 2015USD ($)$ / sharesshares	Apr. 07, 2015USD ($)$ / sharesshares	Nov. 12, 2014USD ($)$ / sharesshares	Nov. 30, 2014USD ($)shares	May. 31, 2014USD ($)shares	Apr. 30, 2014USD ($)shares	Jun. 30, 2012USD ($)shares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Nov. 06, 2014$ / shares	Mar. 31, 2014shares	Dec. 31, 2013shares	Dec. 31, 2012shares
Class Of Stock [Line Items]
Common stock, shares authorized								300,000,000	300,000,000
Common stock, par value | $ / shares								$ 0.0001	$ 0.0001
Preferred stock, shares authorized								5,000,000
Preferred stock, par value | $ / shares								$ 0.0001
Common stock, shares issued								39,005,589	39,005,589
Net proceeds from issuance of common stock | $									$ 85,419
Preferred stock, shares issued								0	0
Proceeds from issuance of convertible preferred stock, net of issuance costs | $									$ 54,660
Proceeds from issuance of convertible preferred stock upon exercise of warrants | $									$ 131
Common stock issued upon, conversion of convertible preferred stock			21,316,519
Stock conversion ratio			1
Convertible preferred stock, shares outstanding									0
Series C Convertible Preferred Stock
Class Of Stock [Line Items]
Issuance price per share of convertible preferred stock | $ / shares									$ 6
Preferred stock, shares issued					5,488,892
Proceeds from issuance of convertible preferred stock, net of issuance costs | $					$ 54,700
Issuance of convertible preferred stock shares upon conversion of convertible promissory notes, Shares					1,058,089				1,058,089
Preferred stock issued in exchange for services					9,997
Series B Convertible Preferred Stock
Class Of Stock [Line Items]
Stock issued for warrant exercised				123,051	4,451,662	4,451,662	57,347
Proceeds from issuance of convertible preferred stock, net of issuance costs | $							$ 1
Proceeds from issuance of convertible preferred stock upon exercise of warrants | $					$ 74	$ 74
Convertible preferred stock, shares outstanding												8,181,576	8,181,576
Series B Convertible Preferred Stock | Bridge Loan
Class Of Stock [Line Items]
Stock issued for warrant exercised					4,279,620	4,279,620
Series A Convertible Preferred Stock
Class Of Stock [Line Items]
Stock issued for warrant exercised				62,251
Convertible preferred stock, shares outstanding												972,330	972,330
Series A and Series B Convertible Preferred Stock
Class Of Stock [Line Items]
Proceeds from issuance of convertible preferred stock upon exercise of warrants | $				$ 57
Common Stock
Class Of Stock [Line Items]
Stock issued for warrant exercised											553,274
IPO
Class Of Stock [Line Items]
Share price | $ / shares										$ 13.50
Common stock, shares issued			6,803,702
Net proceeds from issuance of common stock | $			$ 91,800
Underwriting discounts and commissions | $			6,400
Offering expense | $			5,200					$ 855	$ 4,307
Proceeds from issuance of common stock, net of offering expense | $			$ 80,200
Conversion of convertible preferred stock to common stock in connection with initial public offering, Shares			21,316,519
Stock issued for warrant exercised			185,302
IPO | Series C Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of convertible preferred stock to common stock in connection with initial public offering, Shares									(6,556,978)
IPO | Series B Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of convertible preferred stock to common stock in connection with initial public offering, Shares									(13,724,960)
IPO | Series A Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of convertible preferred stock to common stock in connection with initial public offering, Shares									(1,034,581)
IPO | Common Stock
Class Of Stock [Line Items]
Conversion of convertible preferred stock to common stock in connection with initial public offering, Shares									21,316,519
Stock issued for warrant exercised			491,580
Issuance of common stock, Shares									6,803,702
Over Allotment of Option
Class Of Stock [Line Items]
Common stock, shares issued			507,402
Follow-On Public Offering
Class Of Stock [Line Items]
Underwriting discounts and commissions | $		$ 7,200
Offering expense | $		600
Proceeds from issuance of common stock, net of offering expense | $		$ 112,200
Issuance price per share of convertible preferred stock | $ / shares		$ 29
Issuance of common stock, Shares		4,137,931
Gross proceeds from issuance of common stock | $		$ 120,000
Follow-On Public Offering | Common Stock
Class Of Stock [Line Items]
Issuance of common stock, Shares								4,137,931
Private Placement | Baxalta License Agreement
Class Of Stock [Line Items]
Issuance price per share of convertible preferred stock | $ / shares	$ 25.63
Issuance of common stock, Shares	390,167
Gross proceeds from issuance of common stock | $	$ 10,000
Private Placement | Common Stock
Class Of Stock [Line Items]
Issuance of common stock, Shares								390,167
Amended and Restated Certificate of Incorporation
Class Of Stock [Line Items]
Common stock, shares authorized			300,000,000
Common stock, par value | $ / shares			$ 0.0001
Preferred stock, shares authorized			5,000,000
Preferred stock, par value | $ / shares			$ 0.0001

Stock Option Plans and Stock-64

Stock Option Plans and Stock-Based Compensation - Additional Information (Details) - USD ($)	1 Months Ended					12 Months Ended
	Oct. 31, 2014	Mar. 31, 2014	Jul. 31, 2012	Jan. 31, 2011	Oct. 31, 2010	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued						39,005,589	39,005,589
Common stock, par value						$ 0.0001	$ 0.0001
Options outstanding						7,808,842	5,770,307
Expected dividend yield						$ 0
Share based payment options vested						$ 14,600,000	$ 4,200,000	$ 0
Share based payment options grants, grant-date fair value						$ 18.42	$ 6.65	$ 1.88
Share based payment options exercises value						$ 1,400,000	$ 400,000	$ 0
Unrecognized stock-based compensation expenses related to stock options						$ 55,200,000
Unrecognized share-based compensation related to stock options, period for recognition						3 years 1 month 24 days
Share based payment options grants						3,217,313
Weighted-Average Exercise Price, Granted - at fair value						$ 28.020
2010 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period						4 years
Options granted, expiration period						10 years
Unvested shares of common stock subject to repurchase						0	0
Options outstanding						4,560,904
2014 Equity Incentive Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of shares available for issuance						4.00%
Common stock reserved for future issuance	2,300,000
2014 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	320,000
2014 Employee Stock Purchase Plan | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of shares reserve for issuance	1.00%
Restricted Common Stock (Founders Shares)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued				968,804	4,130,173
Common stock, par value				$ 0.0083	$ 0.0083
Repurchase of common stock, monthly equal installments period				4 years	4 years
Common stock shares repurchased		239,952	286,817
Common stock repurchased, cost per share		$ 0.0083	$ 0.0083
Vesting period						4 years
Stock-based compensation expense						$ 9,000	$ 1,551,000	1,281,000
Restricted Common Stock (Founders Shares) | General and Administrative Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense							4,000	1,054,000
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						14,749,000	5,514,000	740,000
Employee Stock Option | General and Administrative Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						8,289,000	3,934,000	309,000
Employee Stock Option | Former CFO | General and Administrative Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense							1,200,000
Nonemployees Stock-Based Compensation
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						$ 2,000,000	$ 1,300,000	$ 24,000
Share based payment options grants						198,750	113,913	74,983
Weighted-Average Exercise Price, Granted - at fair value						$ 26.51	$ 4.42	$ 1.42

Stock Option Plans and Stock-65

Stock Option Plans and Stock-Based Compensation - Summary of Non-Vested Restricted Stock (Details) - Restricted Common Stock (Founders Shares)	12 Months Ended
	Dec. 31, 2015shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Non-vested, beginning balance	21,245
Number of Shares, Vested	(21,245)

Stock Option Plans and Stock-66

Stock Option Plans and Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Founder's Shares (Details) - Restricted Common Stock (Founders Shares) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 9	$ 1,551	$ 1,281
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 9	1,547	227
General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		$ 4	$ 1,054

Stock Option Plans and Stock-67

Stock Option Plans and Stock-Based Compensation - Summary of Option Activities under 2014 and 2010 Plans (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares Available for Grant, Beginning balance	2,652,500
Shares Available for Grant, Authorized	1,330,319
Shares Available for Grant, Granted - at fair value	(3,217,313)
Shares Available for Grant, Forfeited	317,641
Shares Available for Grant, Ending balance	1,083,147
Number of Options, Beginning balance	5,770,307
Number of Options, Granted - at fair value	3,217,313
Number of Options, Exercised	(861,137)
Number of Options, Forfeited	(317,641)
Number of Options, Ending balance	7,808,842
Weighted-Average Exercise Price, Beginning balance | $ / shares	$ 2.909
Weighted-Average Exercise Price, Granted - at fair value | $ / shares	28.020
Weighted-Average Exercise Price, Exercised | $ / shares	1.660
Weighted-Average Exercise Price, Forfeited | $ / shares	15.066
Weighted-Average Exercise Price, Ending balance | $ / shares	$ 12.898

Stock Option Plans and Stock-68

Stock Option Plans and Stock-Based Compensation - Summary of Additional Information Related to Status of Options (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, Number of Options	7,808,842	5,770,307
Options vested and expected to vest, Number of Options	7,747,817
Options vested and exercisable, Number of Options	3,054,854
Options outstanding, Weighted-Average Exercise Price	$ 12.898	$ 2.909
Options vested and expected to vest, Weighted-Average Exercise Price	12.839
Options vested and exercisable, Weighted-Average Exercise Price	$ 4.956
Options outstanding, Weighted-Average Contractual Terms	8 years 3 months 7 days
Options vested and expected to vest, Weighted-Average Contractual Terms	8 years 3 months 4 days
Options vested and exercisable, Weighted-Average Contractual Terms	7 years 4 months 2 days
Options outstanding, Aggregate Intrinsic Value	$ 94,220
Options vested and expected to vest, Aggregate Intrinsic Value	93,860
Options vested and exercisable, Aggregate Intrinsic Value	$ 56,696

Stock Option Plans and Stock-69

Stock Option Plans and Stock-Based Compensation - Schedule of Weighted Average Assumptions Used to Value Options Granted to Employees (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Expected term (years)	6 years	6 years 6 months	5 years 6 months 4 days
Expected volatility	78.00%	99.00%	108.00%
Risk-free interest rate	1.62%	2.05%	1.23%
Expected dividend yield	0.00%	0.00%	0.00%

Stock Option Plans and Stock-70

Stock Option Plans and Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Options (Details) - Employee Stock Option - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 14,749	$ 5,514	$ 740
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	6,460	1,580	431
General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 8,289	$ 3,934	$ 309

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Statutory U.S. Federal Rate (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Percent of pre-tax income:
U.S. federal statutory income tax rate	34.00%	34.00%	34.00%
State taxes, net of federal benefit	0.70%	(1.65%)	3.97%
Permanent items	(1.25%)	(10.80%)	(12.40%)
Research and development credit	2.46%	3.11%	4.53%
Net operating loss	(0.01%)	0.01%
InteKrin purchase price allocation		0.73%
Other	0.09%	0.02%
Change in valuation allowance	(35.99%)	(25.42%)	(30.10%)
Effective income tax rate	0.00%	0.00%	0.00%

Income Taxes - Components of Ne

Income Taxes - Components of Net Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Components Of Deferred Tax Assets [Abstract]
Net operating loss carryforwards	$ 91,334	$ 34,463
Research and development credits	12,980	6,032
Depreciation and amortization	778	854
Stock-based compensation	5,111	1,428
Other accruals	2,236	940
Deferred revenue	23,237	12,762
Gross deferred tax assets	135,676	56,479
In-process research and development	(891)	(892)
Gross deferred tax liabilities	(891)	(892)
Total net deferred tax asset	134,785	55,587
Less valuation allowance	(134,785)	(55,587)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Loss Carryforwards [Line Items]
Increase in valuation allowance	$ 79,200,000	$ 22,100,000	$ 16,100,000
Tax effect of stock option benefit that will be recorded to equity	7,400,000
Unrecognized tax benefits, accrued interest and penalties accrued	0	0	0
Unrecognized tax benefits	10,605,000	$ 3,816,000	$ 749,000	$ 73,000
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 281,600,000
Net operating loss carryforwards expiration year	2,031
Tax credit carryforwards	$ 15,100,000
Tax credit carryforwards expiration year	2,031
Federal | Stock Options
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 21,700,000
State
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 94,800,000
Net operating loss carryforwards expiration year	2,031
Tax credit carryforwards	$ 5,200,000

Income Taxes - Reconciliation74

Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward
Balance at beginning of year	$ 3,816	$ 749	$ 73
Additions based on tax positions related to current year	3,633	861	319
Additions for tax positions of prior years	3,156	2,206	357
Balance at end of year	$ 10,605	$ 3,816	$ 749

Net Loss Per Share Attributab75

Net Loss Per Share Attributable to Coherus - Computation of Basic and Diluted Net Loss Per Share Attributable to Coherus (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Net loss attributable to Coherus	$ (52,391)	$ (71,334)	$ (58,810)	$ (40,725)	$ (29,134)	$ (7,872)	$ (24,957)	$ (25,170)	$ (223,260)	$ (87,133)	$ (53,635)
Denominator:
Weighted-average common shares outstanding									37,125,617	8,520,100	4,828,214
Less: weighted-average unvested common shares subject to repurchase									(3,609)	(333,571)	(1,496,194)
Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted									37,122,008	8,186,529	3,332,020
Net loss per share attributable to Coherus, basic and diluted	$ (1.35)	$ (1.86)	$ (1.56)	$ (1.22)	$ (1.47)	$ (1.79)	$ (5.96)	$ (6.04)	$ (6.01)	$ (10.64)	$ (16.10)

Net Loss Per Share Attributab76

Net Loss Per Share Attributable to Coherus - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net Loss Per Share Attributable to Coherus (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted net loss per share	7,808,842	5,770,307	16,839,946
Stock Options Outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted net loss per share	7,808,842	5,770,307	3,047,396
Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted net loss per share			9,153,906
Convertible Preferred Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted net loss per share			4,638,644

Net Loss Per Share Attributab77

Net Loss Per Share Attributable to Coherus - Additional Information (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted net loss per share	7,808,842	5,770,307	16,839,946
Restricted Common Stock (Founders Shares)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted net loss per share		358,384

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details)		Jan. 08, 2014USD ($)	Feb. 28, 2014USD ($)	Dec. 31, 2011USD ($)Founders	May. 31, 2014USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Nov. 12, 2014	Sep. 30, 2013USD ($)$ / shares	Dec. 31, 2012shares	Jan. 31, 2012shares
Related Party Transaction [Line Items]
Number of founders entered into notes receivable agreement | Founders				4
Collaboration and license revenue						$ 30,041,000	$ 30,374,000	$ 2,751,000
Research and development expense						213,062,000	78,224,000	31,279,000
Prepaid assets						34,743,000	20,485,000
Accounts payable - related parties						3,548,000	2,020,000
Interest expense from transactions with related party							2,687,000	4,026,000
General and administrative expenses from transactions with related party						559,000	597,000	18,000
Other assets - related party							1,691,000
InteKrin Therapeutics Inc
Related Party Transaction [Line Items]
Business Combination Consideration Transferred1		$ 5,000,000	$ 5,000,000
Bridge Loan
Related Party Transaction [Line Items]
Interest expense from transactions with related party							2,700,000	3,300,000
Investor | Bridge Loan
Related Party Transaction [Line Items]
Aggregate principal amount										$ 10,000,000
Warrant exercise price | $ / shares										$ 0.0167
Prepaid Clinical, Material, Manufacturing and Other - Related Parties
Related Party Transaction [Line Items]
Prepaid assets						10,901,000	5,990,000
Founders
Related Party Transaction [Line Items]
Notes receivable from related parties				$ 133,000
Note receivable interest rate				0.20%
Outstanding balance of notes receivable					$ 111,000
Accrued interest amount forgiven							1,000
Executive Officer
Related Party Transaction [Line Items]
Number of founders entered into notes receivable agreement | Founders				3
Daiichi Sankyo - Related Party
Related Party Transaction [Line Items]
Collaboration and license revenue	[1]					2,239,000	1,893,000	2,025,000
Reduction of research and development expense						16,100,000	7,100,000	1,300,000
Daiichi Sankyo - Related Party | Series B Convertible Preferred Stock
Related Party Transaction [Line Items]
Convertible preferred stock, shares issued | shares												2,867,426
Daiichi Sankyo - Related Party | Minimum
Related Party Transaction [Line Items]
Related party transaction ownership percentage									10.00%
Daiichi Sankyo - Related Party | Maximum
Related Party Transaction [Line Items]
Related party transaction ownership percentage									10.00%
Cook
Related Party Transaction [Line Items]
Research and development expense							4,500,000	6,100,000
Cook | Series B Convertible Preferred Stock
Related Party Transaction [Line Items]
Convertible preferred stock, shares issued | shares											2,150,569	2,150,569
Cook | Minimum
Related Party Transaction [Line Items]
Related party transaction ownership percentage											10.00%	10.00%
Medpace Inc
Related Party Transaction [Line Items]
Research and development expense						42,500,000	24,100,000	4,700,000
Accounts payable - related parties						3,500,000	1,900,000
Interest expense from transactions with related party								500,000
Minimum fee commitment						35,000,000
Medpace Inc | Prepaid Clinical, Material, Manufacturing and Other - Related Parties
Related Party Transaction [Line Items]
Prepaid assets						10,900,000	6,000,000
Medpace Inc | Accrued Clinical, Manufacturing and Other - Related Parties
Related Party Transaction [Line Items]
Accrued and other liabilities						6,100,000	3,000,000
Recruiting Services Provider
Related Party Transaction [Line Items]
Research and development expense						258,000	241,000	35,000
Accounts payable - related parties						0	90,000
General and administrative expenses from transactions with related party						$ 559,000	597,000	$ 18,000
Chief Executive Officer | InteKrin Russia | InteKrin Therapeutics Inc
Related Party Transaction [Line Items]
Related party transaction ownership percentage			10.00%
Officer
Related Party Transaction [Line Items]
Other assets - related party							$ 1,700,000
[1]	Represents revenue from Daiichi Sankyo through November 12, 2014 as a related party, a holder of more than 10% of our common stock until the closing of our initial public offering (“IPO”).

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Subsequent Event	1 Months Ended
	Feb. 29, 2016USD ($)d$ / sharesshares
HRP III Member
Subsequent Event [Line Items]
Aggregate principal amount	$ 75,000,000
KKR Member
Subsequent Event [Line Items]
Aggregate principal amount	20,000,000
MX II Member
Subsequent Event [Line Items]
Aggregate principal amount	4,000,000
KMGCP Member
Subsequent Event [Line Items]
Aggregate principal amount	1,000,000
8.2% Senior Convertible Notes Due 2022
Subsequent Event [Line Items]
Aggregate principal amount	$ 100,000,000
Convertible notes, interest rate	8.20%
Common shares at conversion | shares	44.7387
Conversion price per common share | $ / shares	$ 22.35
Principal amount of notes converted into shares	$ 1,000
Percentage of premium over sale price	60.00%
Percentage of applicable conversion price	160.00%
Convertible trading days | d	20
Convertible consecutive trading days	30 days
Percentage to pay in cash of the par value of notes	109.00%
Debt instrument maturity date	Mar. 31, 2022

Supplementary Data - Quarterl80

Supplementary Data - Quarterly Financial Data (Unaudited) - Schedule of Quarterly Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Total revenue	$ 10,198	$ 7,167	$ 6,866	$ 5,810	$ 6,493	$ 16,052	$ 4,965	$ 3,596	$ 30,041	$ 31,106	$ 2,751
Total operating expenses	62,405	78,384	65,761	42,558	33,053	22,475	22,903	17,357	249,108	95,788	38,744
Net loss	(52,580)	(71,485)	(59,034)	(40,839)	(29,023)	(7,914)	(25,070)	(25,170)	(223,938)	(87,177)	(53,635)
Net loss attributable to Coherus	$ (52,391)	$ (71,334)	$ (58,810)	$ (40,725)	$ (29,134)	$ (7,872)	$ (24,957)	$ (25,170)	$ (223,260)	$ (87,133)	$ (53,635)
Net loss per share attributable to Coherus, basic and diluted	$ (1.35)	$ (1.86)	$ (1.56)	$ (1.22)	$ (1.47)	$ (1.79)	$ (5.96)	$ (6.04)	$ (6.01)	$ (10.64)	$ (16.10)